Report Released Date/Time: Sep 28, 2023@08:08
Provider: BHUSHAN,POOJA
  Specimen: FECES.            SPL 0922 113
    Specimen Collection Date: Sep 21, 2023@19:45
      Test name                Result    units      Ref.   range   Site Code
MICROSPORIDIA SPORE STAIN  NOT DETECTED 
                                                                    [73367]
Comment: MICROSPORIDIA EXAM
         
        REFERENCE RANGE: NOT DETECTED
         
        NOTE: Due to intermittent shedding, one negative sample does
        not necessarily rule out the presence of a parasitic infection.
         
        TEST PERFORMED AT:
        QUEST DIAGNOSTICS/NICHOLS SJC
        33608 ORTEGA HWY
        SAN JUAN CAPISTRANO, CA 92675-2042
        Director: IRINA MARAMICA,MD,PHD,MBA
===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: MI 23 9520 [1223009520]    Received: Sep 22, 2023@08:56
Collection sample: STOOL               Collection date: Sep 21, 2023 19:45
Site/Specimen: FECES
Provider: BHUSHAN,POOJA
                                                                               
                                                                               
 Test(s) ordered: FECAL LEUKOCYTES.............. completed: Sep 23, 2023 13:03

* BACTERIOLOGY FINAL REPORT => Sep 23, 2023 14:44   TECH CODE: 28874
BACTERIOLOGY SMEAR/PREP:
    No fecal leukocytes seen 
                                                                               
                                                                               
=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--
Performing Laboratory:
Bacteriology Report Performed By: 
VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
3350 La Jolla Village Drive San Diego, CA 92161-0002

===============================================================================
 

Report Released Date/Time: Sep 22, 2023@23:45
Provider: BHUSHAN,POOJA
  Specimen: FECES.            IDS 23 18216
    Specimen Collection Date: Sep 21, 2023@19:45
      Test name                Result    units      Ref.   range   Site Code
Giardia Ag                 Negative                Ref: Negative    [664]
Cryptosporidium Ag         Negative                Ref: Negative    [664]
===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: MI 23 9519 [1223009519]    Received: Sep 22, 2023@08:56
Collection sample: STOOL               Collection date: Sep 21, 2023 19:45
Site/Specimen: FECES
Provider: BHUSHAN,POOJA
                                                                               
                                                                               
 Test(s) ordered: CULTURE & SUSCEPTIBILITY...... completed: Sep 25, 2023 11:22

* BACTERIOLOGY FINAL REPORT => Sep 25, 2023 12:50   TECH CODE: 739882
CULTURE RESULTS:  1. SHIGA TOXIN 1&2 NOT DETECTED
                                                                               
                  2. NO SALMONELLA, SHIGELLA, CAMPYLOBACTER, ECOLI H7:0157, OR AEROMONAS SP ISOLATED
                                                                               
                  3. NORMAL INTESTINAL FLORA
                                                                               
                                                                               
=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--
Performing Laboratory:
Bacteriology Report Performed By: 
VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
3350 La Jolla Village Drive San Diego, CA 92161-0002

===============================================================================


Report Released Date/Time: Jul 17, 2025@07:45
Provider: CHEN,KAY JIE
  Specimen: FECES.            NIC 0710 642
    Specimen Collection Date: Jul 10, 2025@06:38
      Test name                Result    units      Ref.   range   Site Code
O&P Concentrate Exam       NO OVA AND PARASITES SEEN 
                                                                    [73367]
O&P Trichrome Exam         NO OVA AND PARASITES SEEN 
                                                                    [73367]
Comment:  
        REFERENCE RANGE: NO OVA AND PARASITES SEEN
         
        Routine Ova and Parasite exam may not detect some
        parasites that occasionally cause diarrheal illness.
        Cryptosporidium Antigen and/or Cyclospora and Isospora
        Exam may be ordered to detect these parasites. One
        negative sample does not necessarily rule out the
        presence of a parasitic infection.
         
        For additional information, please refer to
        https://education.questdiagnostics.com/faq/FAQ203
        (This link is being provided for informational/
        educational purposes only.)
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD
===============================================================================


Report Released Date/Time: Oct 22, 2025@10:43
Provider: GUERRA,JACQUELINE CARINA
  Specimen: SERUM.            CHX 1022 115
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           2.53     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
===============================================================================
 

Report Released Date/Time: Oct 27, 2025@08:29
Provider: ALBAYATI,OKSANA MAYOVSKA
  Specimen: SERUM.            NIC 1022 300
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
ACE                             158 H   U/L        9 - 67           [73367]
Vitamin D3, 1,25 (OH)2           90     pg/mL      Ref: NO REFERENCE RANGE
                                                                    [73367]
Vitamin D2, 1,25 (OH)2           <8     pg/mL      Ref: NO REFERENCE RANGE
                                                                    [73367]
1,25-DI                          90 H   pg/mL      18 - 72          [73367]
Comment: TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
         
        Reference Ranges for Vitamin D, 1,25 (OH)2, Total  pg/mL
         
               < 1 Year   Not established
              1-9 Years   31-87
            10-13 Years   30-83
            14-17 Years   19-83
        > or = 18 Years   18-72
         
        Vitamin D3, 1,25(OH)2 indicates both endogenous production
        and supplementation. Vitamin D2, 1,25(OH)2 is an indicator
        of exogenous sources, such as diet or supplementation.
        Interpretation and therapy are based on measurement of
        Vitamin D, 1,25 (OH)2, Total.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by the FDA. This assay
        has been validated pursuant to the CLIA regulations and is
        used for clinical purposes.
         
        For additional information, please refer to
        http://education.QuestDiagnostics.com/faq/FAQ199
        (This link is being provided for informational/educational
        purposes only.)
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Oct 22, 2025@15:11
Provider: ALBAYATI,OKSANA MAYOVSKA
  Specimen: SERUM.            IM 1022 84
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            40.0     ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Oct 22, 2025@10:43
Provider: ALBAYATI,OKSANA MAYOVSKA
  Specimen: SERUM.            CH 1022 280
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    139     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.1     mMol/L     3.5 - 5.0        [664]
BUN                              32 H   mg/dL      8 - 23           [664]
CREATININE LEVEL               1.79 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       42 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            99     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.5 H   mg/dL      8.5 - 10.4       [664]
AST                              61 H   IU/L       10 - 35          [664]
ALT                              43 H   IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             67     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.7     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.6     g/dL       3.2 - 4.6        [664]
CRP UltraSens                  1.29 H   mg/dL      Ref: <=0.8       [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Oct 22, 2025@10:08
Provider: ALBAYATI,OKSANA MAYOVSKA
  Specimen: BLOOD.            HE 1022 202
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
ESR                              15     mm/hr      0 - 15           [664]
===============================================================================
 

Report Released Date/Time: Oct 22, 2025@10:07
Provider: ALBAYATI,OKSANA MAYOVSKA
  Specimen: BLOOD.            HE 1022 201
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.27     K/uL       4.60 - 10.10     [664]
RBC                            4.05 L   M/uL       4.30 - 5.80      [664]
HGB                            11.5 L   g/dL       12.4 - 17.4      [664]
HCT                            35.2 L   %          38.0 - 52.0      [664]
MCV                            86.9     fL         80.0 - 100.0     [664]
MCH                            28.4     pg         26.0 - 32.0      [664]
MCHC                           32.7     g/dL       31.0 - 35.0      [664]
RDW-SD                         43.2     fL         35.1 - 46.3      [664]
RDW-CV                         13.5     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             292     K/uL       140 - 400        [664]
MPV                             9.7     fL         9.1 - 12.5       [664]
SEGS %                         58.9     %          45.0 - 70.0      [664]
LYMPHS %                       21.6     %          16.0 - 44.0      [664]
MONOS %                        15.0 H   %          5.0 - 12.0       [664]
EOSINO %                        3.2     %          0.4 - 7.5        [664]
BASO %                          1.1 H   %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.10     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.14     K/uL       0.73 - 3.44      [664]
MONO #                         0.79     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.17     K/uL       0.01 - 0.57      [664]
BASO #                         0.06     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Oct 22, 2025@10:43
Provider: ALBAYATI,OKSANA MAYOVSKA
  Specimen: PLASMA.           CHX 1022 114
    Specimen Collection Date: Oct 22, 2025@09:20
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                           7 L   pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Sep 02, 2025@14:40
Provider: YAO,MIMI J
  Specimen: SERUM.            IM 0829 393
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            19.6 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: ~^
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@17:24
Provider: YAO,MIMI J
  Specimen: PLASMA.           CHX 0829 292
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                           9 L   pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: 
Provider: YAO,MIMI J
  Specimen: URINE.            CH 0829 697
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
MICROALBUMIN/CREAT PANEL <<<Test Not Performed 
Comment: *MICROALBUMIN/CREAT PANEL <<< Not Performed: Aug 29, 2025@12:15 by 7
        *NP Reason: DU[LICATE TO CH 694
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@19:52
Provider: YAO,MIMI J
  Specimen: URINE.            UA 0829 105
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                Ref: CLEAR       [664]
URINE COLOR                  YELLOW                YELLOW  -  DARK YELLOW
                                                                    [664]
SPECIFIC GRAVITY              1.016                1.001 - 1.029    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE     Leu/uL     NEGATIVE - 25    [664]
NITRITE, URINE             NEGATIVE                Ref: NEGATIVE    [664]
URINE PH                        5.5                5.0 - 8.0        [664]
URINE BLOOD                NEGATIVE     mg/dL      NEGATIVE - 0.03  [664]
UR PROTEIN                 NEGATIVE     mg/dL      NEGATIVE - 10    [664]
URINE GLUCOSE                 >1000 H   mg/dL      Ref: NORMAL      [664]
URINE KETONES              NEGATIVE     mg/dL      Ref: NEGATIVE-TRACE
                                                                    [664]
UROBILINOGEN,URINE           NORMAL     mg/dL      Ref: NORMAL      [664]
URINE BILIRUBIN            NEGATIVE     mg/dL      Ref: NEGATIVE    [664]
EPITH CELLS                       1     /HPF       0 - 10           [664]
WBC/HPF                           1     /HPF       0 - 5            [664]
RBC/HPF                          <1     /HPF       0 - 5            [664]
Comment: Ascorbic Acid may cause FALSE NEGATIVE Glucose, Bilirubin, Blood,
        and Nitrite dipstick reactions.  
        High glucose and/or protein may increase specific gravity.
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@17:00
Provider: YAO,MIMI J
  Specimen: SERUM.            CHX 0829 291
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
FERRITIN                        219     ng/mL      30 - 400         [664]
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@16:57
Provider: YAO,MIMI J
  Specimen: SERUM.            CH 0829 696
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
Cystatin C                     2.11 H   mg/L       0.62 - 1.15      [664]
eGFR based on Cystatin C       28.5                                 [664]
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.1     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  103     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                              16     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.75 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       43 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            86     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.2     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.5     mg/dL      2.5 - 4.7        [664]
AGAP                             10     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   3.4     g/dL       3.2 - 4.6        [664]
TRANSFERRIN                     193 L   mg/dL      200 - 400        [664]
IRON LEVEL                       36     ug/dl      36 - 160         [664]
IRON SATURATION (%)              13 L   %          20 - 50          [664]
TIBC                            270     ug/dL      228 - 428        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        eGFR calculated using the CKD-EPI Cystatin C equation (2012).
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@16:31
Provider: YAO,MIMI J
  Specimen: BLOOD.            HE 0829 367
    Specimen Collection Date: Aug 29, 2025@11:55
      Test name                Result    units      Ref.   range   Site Code
WBC                            6.57     K/uL       4.60 - 10.10     [664]
RBC                            3.86 L   M/uL       4.30 - 5.80      [664]
HGB                            11.0 L   g/dL       12.4 - 17.4      [664]
HCT                            33.4 L   %          38.0 - 52.0      [664]
MCV                            86.5     fL         80.0 - 100.0     [664]
MCH                            28.5     pg         26.0 - 32.0      [664]
MCHC                           32.9     g/dL       31.0 - 35.0      [664]
RDW-SD                         44.1     fL         35.1 - 46.3      [664]
RDW-CV                         13.9     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             319     K/uL       140 - 400        [664]
MPV                             9.7     fL         9.1 - 12.5       [664]
SEGS %                         67.4     %          45.0 - 70.0      [664]
LYMPHS %                       17.5     %          16.0 - 44.0      [664]
MONOS %                        12.2 H   %          5.0 - 12.0       [664]
EOSINO %                        1.4     %          0.4 - 7.5        [664]
BASO %                          1.2 H   %          0.0 - 1.0        [664]
IG %                            0.3     %          0.1 - 1.1        [664]
SEG #                          4.43     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.15     K/uL       0.73 - 3.44      [664]
MONO #                         0.80     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.09     K/uL       0.01 - 0.57      [664]
BASO #                         0.08     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@16:56
Provider: THOMAS,ROBERT LEE III
  Specimen: URINE.            CH 0829 694
    Specimen Collection Date: Aug 29, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       95.54     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO         12     mg/g       0 - 30           [664]
MICROALBUMIN LEVEL, URINE       1.1     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Sep 08, 2025@08:12
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            NIC 0829 684
    Specimen Collection Date: Aug 29, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
GAD AB                         >250 H   IU/mL      Ref: <=5         [73367]
Comment:  
        This test was performed using the GAD65 ELISA method which
        is standardized against the International reference
        preparation 97/550.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Sep 08, 2025@08:12
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            NIC 0829 672
    Specimen Collection Date: Aug 29, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
INSULIN ANTIBODIES             <0.4     U/mL       Ref: <=0.4       [73367]
C PEPTIDE                      4.60 H   ng/mL      0.80 - 3.85      [73367]
Islet Cell Ab Screen       POSITIVE                Ref: NEGATIVE    [73367]
Islet Cell Ab Titer            2560 H   JDF units  Ref: <=5         [73367]
Comment: TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        normalcy status - Abnormal
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by the FDA. This assay
        has been validated pursuant to the CLIA regulations and is
        used for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
         
        NOTE:  End point titers are compared to a single
        international reference standard and values are reported in
        JDF (Juvenile Diabetes Foundation) units.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Aug 29, 2025@16:11
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            CH 0829 693
    Specimen Collection Date: Aug 29, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.2     mMol/L     3.5 - 5.0        [664]
BUN                              15     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.78 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       42 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            85     mg/dL      70 - 99          [664]
CHOLESTEROL (PRE 12/16/2025)     189    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                             133 H   mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  29     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)      135     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
        eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Sep 03, 2025@08:40
Provider: THOMAS,ROBERT LEE III
  Specimen: BLOOD.            CRCH 0829 236
    Specimen Collection Date: Aug 29, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  5.9     %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        https://ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: May 16, 2025@07:00
Provider: CHEN,KAY JIE
  Specimen: PLASMA.           NIC 0507 483
    Specimen Collection Date: May 07, 2025@13:13
      Test name                Result    units      Ref.   range   Site Code
VITAMIN K1                     1390     pg/mL      130 - 1500       [73367]
Comment:  
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics Nichols Institute Chantilly, VA. It has
        not been cleared or approved by the U.S. Food and Drug
        Administration. This assay has been validated pursuant
        to the CLIA regulations and is used for clinical
        purposes.
         
        TEST PERFORMED AT:
        Quest Diagnostics/Nichols Chantilly
        14225 Newbrook Dr
        Chantilly, VA 20151-2228
        Director: P W Mason MD, PhD
===============================================================================
 

Report Released Date/Time: May 15, 2025@08:06
Provider: CHEN,KAY JIE
  Specimen: SERUM.            NIC 0507 482
    Specimen Collection Date: May 07, 2025@13:13
      Test name                Result    units      Ref.   range   Site Code
CAROTENE, SERUM                  <2 L   mcg/dL     4 - 51           [73367]
Comment:  
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of the results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics Nichols Institute Chantilly, VA. It has
        not been cleared or approved by the U.S. Food and Drug
        Administration. This assay has been validated pursuant
        to the CLIA regulations and is used for clinical
        purposes.
         
        TEST PERFORMED AT:
        Quest Diagnostics/Nichols Chantilly
        14225 Newbrook Dr
        Chantilly, VA 20151-2228
        Director: P W Mason MD, PhD
===============================================================================
 

Report Released Date/Time: May 14, 2025@07:56
Provider: CHEN,KAY JIE
  Specimen: SERUM.            NIC 0507 481
    Specimen Collection Date: May 07, 2025@13:13
      Test name                Result    units      Ref.   range   Site Code
RETINOL                          49     mcg/dL     38 - 98          [73367]
Alpha-Tocopherol (Vit E)       14.8     mg/L       5.7 - 19.9       [73367]
gToco                           1.1     mg/L       Ref: <=4.4       [73367]
Comment: (Note)
         
        **Clin Chem Vol. 34.No.8. pp1625-1628. 1998
        Vitamin supplementation within 24 hours prior to blood
        draw may affect the accuracy of results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        MDF
        med fusion
        2501 South State Highway 121,Suite 1100
        Lewisville TX 75067
        972-966-7300
        Ithiel James L. Frame, MD, PhD
        TEST PERFORMED AT:
        MedFusion
        2501 South State Highway 121, Suite 1100
        Lewisville, TX 75067-8188
        Director: I J Frame MD, PhD
        Levels of alpha-tocopherol <5 mg/L are consistent with
        Vitamin E deficiency in adults.
        (Note)
         
        Vitamin supplementation within 24 hours prior to blood
        draw may affect the accuracy of results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        MDF
        med fusion
        2501 South State Highway 121,Suite 1100
        Lewisville TX 75067
        972-966-7300
        Ithiel James L. Frame, MD, PhD
        TEST PERFORMED AT:
        MedFusion
        2501 South State Highway 121, Suite 1100
        Lewisville, TX 75067-8188
        Director: I J Frame MD, PhD
===============================================================================
 

Report Released Date/Time: May 07, 2025@17:51
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            CH 0507 900
    Specimen Collection Date: May 07, 2025@13:13
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.6     mMol/L     3.5 - 5.0        [664]
BUN                              16     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.55 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       50 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            88     mg/dL      70 - 99          [664]
CHOLESTEROL (PRE 12/16/2025)     189    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                             133 H   mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  31     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)      124     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
        eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: May 09, 2025@11:14
Provider: THOMAS,ROBERT LEE III
  Specimen: BLOOD.            CRCH 0507 268
    Specimen Collection Date: May 07, 2025@13:13
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  6.1     %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        https://ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: May 07, 2025@17:40
Provider: THOMAS,ROBERT LEE III
  Specimen: URINE.            CH 0507 899
    Specimen Collection Date: May 07, 2025@13:13
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       75.27     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO         35 H   mg/g       0 - 30           [664]
MICROALBUMIN LEVEL, URINE       2.6 H   mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Mar 17, 2025@12:57
Provider: YAO,MIMI J
  Specimen: SERUM.            IM 0314 470
    Specimen Collection Date: Mar 14, 2025@15:48
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            14.9 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: ~^
===============================================================================
 

Report Released Date/Time: Mar 14, 2025@18:28
Provider: YAO,MIMI J
  Specimen: PLASMA.           CH 0314 1181
    Specimen Collection Date: Mar 14, 2025@15:48
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                          23     pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Mar 14, 2025@18:58
Provider: YAO,MIMI J
  Specimen: URINE.            CH 0314 1180
    Specimen Collection Date: Mar 14, 2025@15:48
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       79.64     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO         29     mg/g       0 - 30           [664]
MICROALBUMIN LEVEL, URINE       2.3 H   mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Mar 14, 2025@19:39
Provider: YAO,MIMI J
  Specimen: URINE.            UA 0314 150
    Specimen Collection Date: Mar 14, 2025@15:48
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                Ref: CLEAR       [664]
URINE COLOR                  YELLOW                YELLOW  -  DARK YELLOW
                                                                    [664]
SPECIFIC GRAVITY              1.016                1.001 - 1.029    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE     Leu/uL     NEGATIVE - 25    [664]
NITRITE, URINE             NEGATIVE                Ref: NEGATIVE    [664]
URINE PH                        5.5                5.0 - 8.0        [664]
URINE BLOOD                NEGATIVE     mg/dL      NEGATIVE - 0.03  [664]
UR PROTEIN                       10     mg/dL      NEGATIVE - 10    [664]
URINE GLUCOSE                 >1000 H   mg/dL      Ref: NORMAL      [664]
URINE KETONES              NEGATIVE     mg/dL      Ref: NEGATIVE-TRACE
                                                                    [664]
UROBILINOGEN,URINE           NORMAL     mg/dL      Ref: NORMAL      [664]
URINE BILIRUBIN            NEGATIVE     mg/dL      Ref: NEGATIVE    [664]
EPITH CELLS                       1     /HPF       0 - 10           [664]
WBC/HPF                           1     /HPF       0 - 5            [664]
RBC/HPF                           1     /HPF       0 - 5            [664]
Comment: Ascorbic Acid may cause FALSE NEGATIVE Glucose, Bilirubin, Blood,
        and Nitrite dipstick reactions.  
        High glucose and/or protein may increase specific gravity.
===============================================================================
 

Report Released Date/Time: Mar 14, 2025@21:38
Provider: YAO,MIMI J
  Specimen: SERUM.            CH 0314 1179
    Specimen Collection Date: Mar 14, 2025@15:48
      Test name                Result    units      Ref.   range   Site Code
Cystatin C                     1.96 H   mg/L       0.62 - 1.15      [664]
eGFR based on Cystatin C       31.4                                 [664]
SODIUM LEVEL                    139     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.9     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  103     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             21 L   mMol/L     24 - 31          [664]
BUN                              14     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.58 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       49 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            85     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.9     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                4.1     mg/dL      2.5 - 4.7        [664]
AGAP                             15     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   4.0     g/dL       3.2 - 4.6        [664]
FERRITIN                        221     ng/mL      30 - 400         [664]
TRANSFERRIN                     236     mg/dL      200 - 400        [664]
IRON LEVEL                       58     ug/dl      36 - 160         [664]
IRON SATURATION (%)              18 L   %          20 - 50          [664]
TIBC                            330     ug/dL      228 - 428        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        eGFR calculated using the CKD-EPI Cystatin C equation (2012).
===============================================================================
 

Report Released Date/Time: Mar 14, 2025@16:32
Provider: YAO,MIMI J
  Specimen: BLOOD.            HE 0314 510
    Specimen Collection Date: Mar 14, 2025@15:48
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.92     K/uL       4.60 - 10.10     [664]
RBC                            4.18 L   M/uL       4.30 - 5.80      [664]
HGB                            12.0 L   g/dL       12.4 - 17.4      [664]
HCT                            35.9 L   %          38.0 - 52.0      [664]
MCV                            85.9     fL         80.0 - 100.0     [664]
MCH                            28.7     pg         26.0 - 32.0      [664]
MCHC                           33.4     g/dL       31.0 - 35.0      [664]
RDW-SD                         40.3     fL         35.1 - 46.3      [664]
RDW-CV                         13.0     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             295     K/uL       140 - 400        [664]
MPV                            10.0     fL         9.1 - 12.5       [664]
SEGS %                         56.2     %          45.0 - 70.0      [664]
LYMPHS %                       28.4     %          16.0 - 44.0      [664]
MONOS %                        12.2 H   %          5.0 - 12.0       [664]
EOSINO %                        2.2     %          0.4 - 7.5        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.3     %          0.1 - 1.1        [664]
SEG #                          3.33     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.68     K/uL       0.73 - 3.44      [664]
MONO #                         0.72     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.13     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Feb 25, 2025@16:30
Provider: THOMAS,ROBERT LEE III
  Specimen: URINE.            CH 0225 745
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       70.71     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO         24     mg/g       0 - 30           [664]
MICROALBUMIN LEVEL, URINE       1.7     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Mar 03, 2025@07:26
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            NIC 0225 413
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
GAD AB                         >250 H   IU/mL      Ref: <=5         [73367]
Comment:  
        This test was performed using the GAD65 ELISA method which
        is standardized against the International reference
        preparation 97/550.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Mar 03, 2025@07:26
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            NIC 0225 410
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
INSULIN                         2.7     uIU/mL     Ref: <= 18.4     [73367]
C PEPTIDE                      2.96     ng/mL      0.80 - 3.85      [73367]
Comment:  
        Risk:
        Optimal < or = 18.4
        Moderate NA
        High >18.4
         
        Adult cardiovascular event risk category cut points
        (optimal, moderate, high) are based on Insulin Reference
        interval studies performed at Quest Diagnostics in 2022.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Feb 25, 2025@16:30
Provider: THOMAS,ROBERT LEE III
  Specimen: SERUM.            CH 0225 743
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    140     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.7     mMol/L     3.5 - 5.0        [664]
BUN                              13     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.45 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       54 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            75     mg/dL      70 - 99          [664]
CHOLESTEROL (PRE 12/16/2025)     202    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                             138 H   mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  46     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       92     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
        eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Feb 26, 2025@10:30
Provider: THOMAS,ROBERT LEE III
  Specimen: BLOOD.            CRCH 0225 212
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  5.8     %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        https://ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Feb 25, 2025@16:00
Provider: LAVASANI,REBECCA
  Specimen: BLOOD.            HE 0225 344
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.94     K/uL       4.60 - 10.10     [664]
RBC                            4.02 L   M/uL       4.30 - 5.80      [664]
HGB                            11.5 L   g/dL       12.4 - 17.4      [664]
HCT                            35.2 L   %          38.0 - 52.0      [664]
MCV                            87.6     fL         80.0 - 100.0     [664]
MCH                            28.6     pg         26.0 - 32.0      [664]
MCHC                           32.7     g/dL       31.0 - 35.0      [664]
RDW-SD                         42.6     fL         35.1 - 46.3      [664]
RDW-CV                         13.2     %          11.0 - 15.0      [664]
PLT                             287     K/uL       140 - 400        [664]
MPV                            10.2     fL         9.1 - 12.5       [664]
Reticulocyte, Auto (%)         1.55     %          0.95 - 2.68      [664]
Retics, Absolute              0.062     x10E6/uL   0.045 - 0.133    [664]
IRF                            11.6     %          2.3 - 15.9       [664]
RET-He                         32.9     pg         28.3 - 39.5      [664]
===============================================================================
 

Report Released Date/Time: Feb 25, 2025@16:30
Provider: LAVASANI,REBECCA
  Specimen: SERUM.            CH 0225 741
    Specimen Collection Date: Feb 25, 2025@11:54
      Test name                Result    units      Ref.   range   Site Code
FERRITIN                        214     ng/mL      30 - 400         [664]
TRANSFERRIN                     219     mg/dL      200 - 400        [664]
IRON LEVEL                       62     ug/dl      36 - 160         [664]
IRON SATURATION (%)              20     %          20 - 50          [664]
TIBC                            307     ug/dL      228 - 428        [664]
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@11:10
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: URINE.            CH 1216 390
    Specimen Collection Date: Dec 16, 2024@09:37
      Test name                Result    units      Ref.   range   Site Code
PROTEIN, URINE                   13 H   mg/dL      NEGATIVE - 10    [664]
CREATININE, URINE              52.5     mg/dL                       [664]
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@11:03
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: PLASMA.           CH 1216 389
    Specimen Collection Date: Dec 16, 2024@09:37
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                          28     pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@11:05
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: URINE.            UA 1216 45
    Specimen Collection Date: Dec 16, 2024@09:37
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                Ref: CLEAR       [664]
URINE COLOR                COLORLESS               YELLOW  -  DARK YELLOW
                                                                    [664]
SPECIFIC GRAVITY              1.012                1.001 - 1.029    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE     Leu/uL     NEGATIVE - 25    [664]
NITRITE, URINE             NEGATIVE                Ref: NEGATIVE    [664]
URINE PH                      <=5.0 L              5.0 - 8.0        [664]
URINE BLOOD                NEGATIVE     mg/dL      NEGATIVE - 0.03  [664]
UR PROTEIN                 NEGATIVE     mg/dL      NEGATIVE - 10    [664]
URINE GLUCOSE                 >1000 H   mg/dL      Ref: NORMAL      [664]
URINE KETONES              NEGATIVE     mg/dL      Ref: NEGATIVE-TRACE
                                                                    [664]
UROBILINOGEN,URINE           NORMAL     mg/dL      Ref: NORMAL      [664]
URINE BILIRUBIN            NEGATIVE     mg/dL      Ref: NEGATIVE    [664]
EPITH CELLS                      <1     /HPF       0 - 10           [664]
RBC/HPF                          <1     /HPF       0 - 5            [664]
Comment: Ascorbic Acid may cause FALSE NEGATIVE Glucose, Bilirubin, Blood,
        and Nitrite dipstick reactions.  
        High glucose and/or protein may increase specific gravity.
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@11:03
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: SERUM.            CH 1216 388
    Specimen Collection Date: Dec 16, 2024@09:37
      Test name                Result    units      Ref.   range   Site Code
Cystatin C                     1.70 H   mg/L       0.62 - 1.15      [664]
eGFR based on Cystatin C       38.0                                 [664]
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.0     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  105     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             21 L   mMol/L     24 - 31          [664]
BUN                              18     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.44 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       55 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            80     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.9     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.8     mg/dL      2.5 - 4.7        [664]
AGAP                             12     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        eGFR calculated using the CKD-EPI Cystatin C equation (2012).
===============================================================================
 

Report Released Date/Time: 
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: BLOOD.            HE 1216 229
    Specimen Collection Date: Dec 16, 2024@09:37
      Test name                Result    units      Ref.   range   Site Code
CBC                        Test Not Performed 
Comment: *CBC Not Performed: Dec 16, 2024@15:56 by 632555
        *NP Reason: REF HE 1216 227
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@10:48
Provider: ABIALMOUNA,OMAR JIHAD
  Specimen: BLOOD.            HE 1216 228
    Specimen Collection Date: Dec 16, 2024@09:36
      Test name                Result    units      Ref.   range   Site Code
ESR                              10     mm/hr      0 - 15           [664]
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@10:27
Provider: ABIALMOUNA,OMAR JIHAD
  Specimen: BLOOD.            HE 1216 227
    Specimen Collection Date: Dec 16, 2024@09:36
      Test name                Result    units      Ref.   range   Site Code
WBC                            6.04     K/uL       4.60 - 10.10     [664]
RBC                            4.02 L   M/uL       4.30 - 5.80      [664]
HGB                            11.7 L   g/dL       12.4 - 17.4      [664]
HCT                            34.7 L   %          38.0 - 52.0      [664]
MCV                            86.3     fL         80.0 - 100.0     [664]
MCH                            29.1     pg         26.0 - 32.0      [664]
MCHC                           33.7     g/dL       31.0 - 35.0      [664]
RDW-SD                         42.7     fL         35.1 - 46.3      [664]
RDW-CV                         13.5     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             276     K/uL       140 - 400        [664]
MPV                             9.7     fL         9.1 - 12.5       [664]
SEGS %                         59.1     %          45.0 - 70.0      [664]
LYMPHS %                       24.8     %          16.0 - 44.0      [664]
MONOS %                        12.6 H   %          5.0 - 12.0       [664]
EOSINO %                        2.6     %          0.4 - 7.5        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.57     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.50     K/uL       0.73 - 3.44      [664]
MONO #                         0.76     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.16     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Dec 16, 2024@10:57
Provider: ABIALMOUNA,OMAR JIHAD
  Specimen: SERUM.            CH 1216 387
    Specimen Collection Date: Dec 16, 2024@09:36
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.0     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  104     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             23 L   mMol/L     24 - 31          [664]
BUN                              18     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.50 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       52 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            83     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.9     mg/dL      8.5 - 10.4       [664]
AGAP                             11     mMol/L     6 - 15           [664]
AST                              31     IU/L       10 - 35          [664]
ALT                              26     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             57     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.5     mg/dL      0.4 - 1.2        [664]
DIRECT BILIRUBIN                0.1     mg/dL      0 - 0.2          [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
PROTEIN, TOTAL                  6.5     g/dL       6.0 - 8.0        [664]
CRP UltraSens                  0.78     mg/dL      Ref: <=0.8       [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Aug 30, 2024@18:28
Provider: FRINK,BRIANA
  Specimen: SERUM.            CH 0830 852
    Specimen Collection Date: Aug 30, 2024@13:38
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.6     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  102     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             21 L   mMol/L     24 - 31          [664]
BUN                              17     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.47 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       54 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            95     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.5     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.4     mg/dL      2.5 - 4.7        [664]
AGAP                             13     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   4.0     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Aug 30, 2024@23:12
Provider: FRINK,BRIANA
  Specimen: URINE.            CH 0830 850
    Specimen Collection Date: Aug 30, 2024@13:38
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       65.17     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.04 H   mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       2.7 H   mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Aug 31, 2024@10:08
Provider: FRINK,BRIANA
  Specimen: BLOOD.            CRCH 0830 222
    Specimen Collection Date: Aug 30, 2024@13:38
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  9.0 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        https://ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Aug 30, 2024@17:43
Provider: FOX,KYLE M
  Specimen: SERUM.            CH 0830 849
    Specimen Collection Date: Aug 30, 2024@13:38
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.6     mMol/L     3.5 - 5.0        [664]
BUN                              17     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.49 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       53 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            93     mg/dL      70 - 99          [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Aug 30, 2024@17:57
Provider: LAVASANI,REBECCA
  Specimen: BLOOD.            HE 0830 378
    Specimen Collection Date: Aug 30, 2024@13:37
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.64     K/uL       4.60 - 10.10     [664]
RBC                            3.95 L   M/uL       4.30 - 5.80      [664]
HGB                            11.2 L   g/dL       12.4 - 17.4      [664]
HCT                            34.6 L   %          38.0 - 52.0      [664]
MCV                            87.6     fL         80.0 - 100.0     [664]
MCH                            28.4     pg         26.0 - 32.0      [664]
MCHC                           32.4     g/dL       31.0 - 35.0      [664]
RDW-SD                         42.5     fL         35.1 - 46.3      [664]
RDW-CV                         13.2     %          11.0 - 15.0      [664]
PLT                             316     K/uL       140 - 400        [664]
MPV                            10.1     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Aug 30, 2024@18:28
Provider: LAVASANI,REBECCA
  Specimen: SERUM.            CH 0830 847
    Specimen Collection Date: Aug 30, 2024@13:37
      Test name                Result    units      Ref.   range   Site Code
FERRITIN                         74     ng/mL      30 - 400         [664]
TRANSFERRIN                     227     mg/dL      200 - 400        [664]
IRON LEVEL                       76     ug/dl      36 - 160         [664]
IRON SATURATION (%)              24     %          20 - 50          [664]
TIBC                            318     ug/dL      228 - 428        [664]
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@13:01
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: SERUM.            CH 0628 578
    Specimen Collection Date: Jun 28, 2024@11:31
      Test name                Result    units      Ref.   range   Site Code
ALKALINE PHOSPHATASE             51     IU/L       38 - 126         [664]
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@15:20
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: SERUM.            IM 0628 247
    Specimen Collection Date: Jun 28, 2024@11:31
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            20.2 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: ~^
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@12:48
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: PLASMA.           CH 0628 576
    Specimen Collection Date: Jun 28, 2024@11:31
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                          63     pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@13:04
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: URINE.            CH 0628 575
    Specimen Collection Date: Jun 28, 2024@11:30
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       59.33     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.09 H   mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       5.1 H   mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@12:01
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: URINE.            UA 0628 93
    Specimen Collection Date: Jun 28, 2024@11:30
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                Ref: CLEAR       [664]
URINE COLOR                COLORLESS               YELLOW  -  DARK YELLOW
                                                                    [664]
SPECIFIC GRAVITY              1.011                1.001 - 1.029    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE     Leu/uL     NEGATIVE - 25    [664]
NITRITE, URINE             NEGATIVE                Ref: NEGATIVE    [664]
URINE PH                        6.0                5.0 - 8.0        [664]
URINE BLOOD                NEGATIVE     mg/dL      NEGATIVE - 0.03  [664]
UR PROTEIN                       20 H   mg/dL      NEGATIVE - 10    [664]
URINE GLUCOSE                  1000 H   mg/dL      Ref: NORMAL      [664]
URINE KETONES              NEGATIVE     mg/dL      Ref: NEGATIVE-TRACE
                                                                    [664]
UROBILINOGEN,URINE           NORMAL     mg/dL      Ref: NORMAL      [664]
URINE BILIRUBIN            NEGATIVE     mg/dL      Ref: NEGATIVE    [664]
WBC/HPF                           1     /HPF       0 - 5            [664]
RBC/HPF                           1     /HPF       0 - 5            [664]
Comment: Ascorbic Acid may cause FALSE NEGATIVE Glucose, Bilirubin, Blood,
        and Nitrite dipstick reactions.  
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@14:15
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: SERUM.            CH 0628 574
    Specimen Collection Date: Jun 28, 2024@11:30
      Test name                Result    units      Ref.   range   Site Code
Cystatin C                     1.58 H   mg/L       0.62 - 1.15      [664]
eGFR based on Cystatin C       42.0                                 [664]
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.6     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  101     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                              16     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.42 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       56 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           251 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.3     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.9     mg/dL      2.5 - 4.7        [664]
AGAP                             12     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   3.6     g/dL       3.2 - 4.6        [664]
FERRITIN                         92     ng/mL      30 - 400         [664]
TRANSFERRIN                     232     mg/dL      200 - 400        [664]
IRON LEVEL                       66     ug/dl      36 - 160         [664]
IRON SATURATION (%)              20     %          20 - 50          [664]
TIBC                            325     ug/dL      228 - 428        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        eGFR calculated using the CKD-EPI Cystatin C equation (2012).
===============================================================================
 

Report Released Date/Time: Jul 01, 2024@13:42
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: BLOOD.            CRCH 0628 259
    Specimen Collection Date: Jun 28, 2024@11:30
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                 15.0 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        https://ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@12:02
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: BLOOD.            HE 0628 296
    Specimen Collection Date: Jun 28, 2024@11:30
      Test name                Result    units      Ref.   range   Site Code
WBC                            7.35     K/uL       4.60 - 10.10     [664]
RBC                            3.65 L   M/uL       4.30 - 5.80      [664]
HGB                            10.5 L   g/dL       12.4 - 17.4      [664]
HCT                            31.2 L   %          38.0 - 52.0      [664]
MCV                            85.5     fL         80.0 - 100.0     [664]
MCH                            28.8     pg         26.0 - 32.0      [664]
MCHC                           33.7     g/dL       31.0 - 35.0      [664]
RDW-SD                         38.4     fL         35.1 - 46.3      [664]
RDW-CV                         12.2     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             317     K/uL       140 - 400        [664]
MPV                             9.9     fL         9.1 - 12.5       [664]
SEGS %                         79.5 H   %          45.0 - 70.0      [664]
LYMPHS %                       14.7 L   %          16.0 - 44.0      [664]
MONOS %                         5.2     %          5.0 - 12.0       [664]
EOSINO %                        0.1 L   %          0.4 - 7.5        [664]
BASO %                          0.1     %          0.0 - 1.0        [664]
IG %                            0.4     %          0.1 - 1.1        [664]
SEG #                          5.84     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.08     K/uL       0.73 - 3.44      [664]
MONO #                         0.38     K/uL       0.25 - 0.97      [664]
EOSINO #                      <0.03     K/uL       0.01 - 0.57      [664]
BASO #                        <0.03     K/uL       0.01 - 0.10      [664]
IG #                           0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: 
Provider: ABIALMOUNA,OMAR JIHAD
  Specimen: BLOOD.            HE 0628 294
    Specimen Collection Date: Jun 28, 2024@11:29
      Test name                Result    units      Ref.   range   Site Code
CBC & DIFF                 Test Not Performed 
Comment: *CBC & DIFF Not Performed: Jun 28, 2024@13:06 by 676122
        *NP Reason: DUPLICATE REF HE 296
===============================================================================
 

Report Released Date/Time: Jun 28, 2024@13:04
Provider: MAO,JIMMY JINGLI
  Specimen: SERUM.            CH 0628 571
    Specimen Collection Date: Jun 28, 2024@11:29
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.5     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  101     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             25     mMol/L     24 - 31          [664]
BUN                              16     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.44 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       55 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           252 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.3     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.8     mg/dL      2.5 - 4.7        [664]
AGAP                             10     mMol/L     6 - 15           [664]
AST                              23     IU/L       10 - 35          [664]
ALT                              23     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             52     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.5     mg/dL      0.4 - 1.2        [664]
DIRECT BILIRUBIN               <0.1     mg/dL      0 - 0.2          [664]
ALBUMIN LEVEL                   3.5     g/dL       3.2 - 4.6        [664]
PROTEIN, TOTAL                  6.4     g/dL       6.0 - 8.0        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: May 24, 2024@10:57
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: PLASMA.           CH 0524 335
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
BNP (PRE 12/16/2025)          <35.0     pg/mL      2 - 100          [664]
===============================================================================
 

Report Released Date/Time: May 28, 2024@11:39
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: SERUM.            IM 0524 453
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            26.3 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: ~^
===============================================================================
 

Report Released Date/Time: May 24, 2024@10:54
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: PLASMA.           CH 0524 334
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                          42     pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: May 24, 2024@11:16
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: URINE.            CH 0524 333
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       35.40     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.13 H   mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       4.5 H   mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: May 24, 2024@11:11
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: URINE.            CH 0524 332
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
PROTEIN, URINE                   20 H   mg/dL      NEGATIVE - 10    [664]
CREATININE, URINE              35.8     mg/dL                       [664]
===============================================================================
 

Report Released Date/Time: May 24, 2024@10:44
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: URINE.            UA 0524 38
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                Ref: CLEAR       [664]
URINE COLOR                COLORLESS               YELLOW  -  DARK YELLOW
                                                                    [664]
SPECIFIC GRAVITY              1.016                1.001 - 1.029    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE     Leu/uL     NEGATIVE - 25    [664]
NITRITE, URINE             NEGATIVE                Ref: NEGATIVE    [664]
URINE PH                        6.5                5.0 - 8.0        [664]
URINE BLOOD                NEGATIVE     mg/dL      NEGATIVE - 0.03  [664]
UR PROTEIN                 NEGATIVE     mg/dL      NEGATIVE - 10    [664]
URINE GLUCOSE                 >1000 H   mg/dL      Ref: NORMAL      [664]
URINE KETONES              NEGATIVE     mg/dL      Ref: NEGATIVE-TRACE
                                                                    [664]
UROBILINOGEN,URINE           NORMAL     mg/dL      Ref: NORMAL      [664]
URINE BILIRUBIN            NEGATIVE     mg/dL      Ref: NEGATIVE    [664]
WBC/HPF                           1     /HPF       0 - 5            [664]
RBC/HPF                          <1     /HPF       0 - 5            [664]
Comment: Ascorbic Acid may cause FALSE NEGATIVE Glucose, Bilirubin, Blood,
        and Nitrite dipstick reactions.  
        High glucose and/or protein may increase specific gravity.
===============================================================================
 

Report Released Date/Time: May 24, 2024@11:16
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: SERUM.            CH 0524 331
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
Cystatin C                     2.15 H   mg/L       0.62 - 1.15      [664]
eGFR based on Cystatin C       27.9                                 [664]
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.1     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  103     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             27     mMol/L     24 - 31          [664]
BUN                              23     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.71 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       45 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           382 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.1     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.5     mg/dL      2.5 - 4.7        [664]
AGAP                              8     mMol/L     6 - 15           [664]
URIC ACID LEVEL                 3.8     mg/dL      3.5 - 7.2        [664]
AST                              14     IU/L       10 - 35          [664]
ALT                              15     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             60     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.5     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     197    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              81     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                 106     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       48     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
FERRITIN                        194     ng/mL      30 - 400         [664]
TRANSFERRIN                     256     mg/dL      200 - 400        [664]
IRON LEVEL                       70     ug/dl      36 - 160         [664]
IRON SATURATION (%)              20     %          20 - 50          [664]
TIBC                            358     ug/dL      228 - 428        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        eGFR calculated using the CKD-EPI Cystatin C equation (2012).
===============================================================================
 

Report Released Date/Time: May 28, 2024@11:03
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: BLOOD.            CRCH 0524 119
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  9.2 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        https://ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: May 24, 2024@10:13
Provider: DE SOUZA FILGUEIRAS PINTO,RACHEL
  Specimen: BLOOD.            HE 0524 188
    Specimen Collection Date: May 24, 2024@09:11
      Test name                Result    units      Ref.   range   Site Code
WBC                            7.49     K/uL       4.60 - 10.10     [664]
RBC                            3.31 L   M/uL       4.30 - 5.80      [664]
HGB                             9.8 L   g/dL       12.4 - 17.4      [664]
HCT                            28.4 L   %          38.0 - 52.0      [664]
MCV                            85.8     fL         80.0 - 100.0     [664]
MCH                            29.6     pg         26.0 - 32.0      [664]
MCHC                           34.5     g/dL       31.0 - 35.0      [664]
RDW-SD                         38.1     fL         35.1 - 46.3      [664]
RDW-CV                         12.2     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             320     K/uL       140 - 400        [664]
MPV                            10.2     fL         9.1 - 12.5       [664]
SEGS %                         63.1     %          45.0 - 70.0      [664]
LYMPHS %                       25.0     %          16.0 - 44.0      [664]
MONOS %                        10.9     %          5.0 - 12.0       [664]
EOSINO %                        0.4     %          0.4 - 7.5        [664]
BASO %                          0.5     %          0.0 - 1.0        [664]
IG %                            0.1     %          0.1 - 1.1        [664]
SEG #                          4.72     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.87     K/uL       0.73 - 3.44      [664]
MONO #                         0.82     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.03     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: 
Provider: GU,KELLY MONJIA
  Specimen: SERUM.            CH 0430 1200
    Specimen Collection Date: Apr 30, 2024@14:28
      Test name                Result    units      Ref.   range   Site Code
RENAL FUNCTION PANEL       Test Not Performed 
Comment: *RENAL FUNCTION PANEL Not Performed: Apr 30, 2024@15:48 by 737365
        *NP Reason: PT REFUSE TEST REF#721076
===============================================================================
 

Report Released Date/Time: Apr 30, 2024@20:30
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: URINE.            UA 0430 168
    Specimen Collection Date: Apr 30, 2024@14:27
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.008                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: <NEGATIVE   [664]
NITRITE, URINE             NEGATIVE                Ref: <NEGATIVE   [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                      1+ H              Ref: <NEGATIVE   [664]
UR PROTEIN                       1+ H              Ref: <NEGATIVE   [664]
URINE GLUCOSE                    3+ H              Ref: <NEGATIVE   [664]
URINE KETONES              NEGATIVE                Ref: <NEGATIVE   [664]
UROBILINOGEN,URINE             <2.0     mg/dL      Ref: <=2.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: <NEGATIVE   [664]
HYALINE CASTS                  5-10 H   /LPF       0 - 4            [664]
EPITH CELLS                     FEW H              Ref: 0           [664]
WBC/HPF                         3-5 H   /HPF       0 - 2            [664]
RBC/HPF                         3-5 H   /HPF       0 - 2            [664]
Comment: Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
===============================================================================
 

Report Released Date/Time: Apr 30, 2024@22:32
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: URINE.            CH 0430 1198
    Specimen Collection Date: Apr 30, 2024@14:27
      Test name                Result    units      Ref.   range   Site Code
PROTEIN, URINE                   59     mg/dL                       [664]
CREATININE, URINE              55.6     mg/dL                       [664]
===============================================================================
 

Report Released Date/Time: Apr 29, 2024@17:18
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: BLOOD.            HE 0429 595
    Specimen Collection Date: Apr 29, 2024@16:32
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.53     K/uL       4.60 - 10.10     [664]
RBC                            3.46 L   M/uL       4.30 - 5.80      [664]
HGB                            10.1 L   g/dL       12.4 - 17.4      [664]
HCT                            30.1 L   %          38.0 - 52.0      [664]
MCV                            87.0     fL         80.0 - 100.0     [664]
MCH                            29.2     pg         26.0 - 32.0      [664]
MCHC                           33.6     g/dL       31.0 - 35.0      [664]
RDW-SD                         39.8     fL         35.1 - 46.3      [664]
RDW-CV                         12.5     %          11.0 - 15.0      [664]
PLT                             353     K/uL       140 - 400        [664]
MPV                             9.3     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Apr 29, 2024@17:30
Provider: NGUYEN,ANTHONY TRUONG MANH
  Specimen: SERUM.            CH 0429 1198
    Specimen Collection Date: Apr 29, 2024@16:32
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.1 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  101     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             23 L   mMol/L     24 - 31          [664]
BUN                              18     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.36 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       30 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           163 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.5 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.1     mg/dL      2.5 - 4.7        [664]
AGAP                             13     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   4.1     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 27, 2024@14:19
Provider: GU,KELLY MONJIA
  Specimen: NARES.            IDS 24 8697
    Specimen Collection Date: Apr 25, 2024@16:58
      Test name                Result    units      Ref.   range   Site Code
MRSA SURVL NARES AGAR      Negative                Ref: Negative    [664]
===============================================================================
 

Report Released Date/Time: Apr 25, 2024@12:36
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0425 152
    Specimen Collection Date: Apr 25, 2024@12:35
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 129 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:296093, Serial Number:UU14527309
===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: FUN 24 457 [3724000457]    Received: Apr 25, 2024@13:33
Collection sample: BRONCHOALVEOLAR LAVAGECollection date: Apr 25, 2024 11:58
Site/Specimen: BRONCHIAL WASHING 
Provider: KEMP,SARAH ELEANOR
                                                                               
                                                                               
 Test(s) ordered: MYCOLOGY CULTURE.............. completed: May 30, 2024 08:13

* MYCOLOGY FINAL REPORT => May 30, 2024 08:16   TECH CODE: 625647
Mycology Remark(s):
  NO PATHOGENIC FUNGUS ISOLATED AFTER 4 WEEKS 
                                                                               
=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--
Performing Laboratory:
Mycology Report Performed By: 
VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
3350 La Jolla Village Drive San Diego, CA 92161-0002

===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: TB 24 533 [3524000533]     Received: Apr 25, 2024@13:33
Collection sample: BRONCHOALVEOLAR LAVAGECollection date: Apr 25, 2024 11:58
Site/Specimen: BRONCHIAL WASHING 
Provider: KEMP,SARAH ELEANOR
                                                                               
                                                                               
 Test(s) ordered: AFB CULTURE & SMEAR........... completed: Jun 24, 2024 12:02
                  AFB SMEAR..................... completed: Apr 26, 2024 15:19

* MYCOBACTERIOLOGY FINAL REPORT => Jun 24, 2024 12:03   TECH CODE: 739882
Concentrate Acid Fast Stain:  Negative
                                                                               
Mycobacteriology Remark(s):
  NO MYCOBACTERIUM ISOLATED AFTER 8 WEEKS 
                                                                               
=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--
Performing Laboratory:
Mycobacteriology Report Performed By: 
VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
3350 La Jolla Village Drive San Diego, CA 92161-0002

===============================================================================
 

Report Released Date/Time: Apr 25, 2024@18:05
Provider: KEMP,SARAH ELEANOR
  Specimen: BRONCHIAL WASHING HE 0425 393
    Specimen Collection Date: Apr 25, 2024@11:58
      Test name                Result    units      Ref.   range   Site Code
COLOR                           Red                                 [664]
APPEARANCE                   Cloudy                                 [664]
WBC fluid #                      56     WBC/uL     Ref: see eval    [664]
      Eval: No reference range established
RBC fluid #                   16.15     K/uL       Ref: see eval    [664]
      Eval: No reference range established
NEUTROPHIL Man % Fluid           54     %          Ref: see eval    [664]
      Eval: No reference range established
LYMPHOCYTE Man % Fluid           11     %          Ref: see eval    [664]
      Eval: No reference range established
MACROPHAGE Man % Fluid           35     %          Ref: see eval    [664]
      Eval: No reference range established
===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: MI 24 4182 [1224004182]    Received: Apr 25, 2024@13:33
Collection sample: BRONCHOALVEOLAR LAVAGECollection date: Apr 25, 2024 11:58
Site/Specimen: BRONCHIAL WASHING 
Provider: KEMP,SARAH ELEANOR
                                                                               
                                                                               
 Test(s) ordered: CULTURE & SUSCEPTIBILITY...... completed: May 02, 2024 09:43
                  GRAM STAIN.................... completed: Apr 26, 2024 12:15
                  LEGIONELLA CULTURE............ completed: May 02, 2024 09:43

* BACTERIOLOGY FINAL REPORT => May 02, 2024 11:18   TECH CODE: 28874
GRAM STAIN: NO EPITHELIAL CELLS 
            NO POLYMORPHONUCLEAR CELLS 
            NO ORGANISMS SEEN 
            ***GRAM STAIN 
                                                                               
Bacteriology Remark(s):
  1+ PHARYNGEAL FLORA PRESENT 
  NO LEGIONELLA ISOLATED 
                                                                               
=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--
Performing Laboratory:
Bacteriology Report Performed By: 
VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
3350 La Jolla Village Drive San Diego, CA 92161-0002

===============================================================================
 

Report Released Date/Time: Apr 26, 2024@16:49
Provider: KEMP,SARAH ELEANOR
  Specimen: TISSUE.           FC 0425 30
    Specimen Collection Date: Apr 25, 2024@11:36
      Test name                Result    units      Ref.   range   Site Code
IMMUNOPHENOTYPING           comment                                 [664]
Viability, Immunophenotyping   47.87    %                           [664]
Interpretation Rendered By:Kyle Backer, MD 
                                                                    [664]
FLOW MARKER X19                 YES                                 [664]
Comment: ~For Test: FLOW CYTOMETRY FOR LEUKEMIA/LYMPHOMA
        ~EBUS station 7 LN
        Interpretation: No monotypic B-cell or aberrant T-cell population
        identified within low viability specimen.  
        ~
        Phenotype: N/A
        ~
        Note: Immunophenotypic analysis of a FNA specimen was performed by
        flow cytometry.  
        ~
        Approximately 27% of the total cells are CD45 bright positive with
        low side scatter, consistent with lymphocytes. Approximately 3.12%
        of the total cells (11.67% of lymphocytes) are B-cells (CD19+) with
        no evidence of light chain restriction (kappa:lambda ratio of
        0.75). Approximately 21% of the total cells (78% of lymphocytes)
        are T-cells (CD3+) with a CD4:CD8 ratio of 3.65. Approximately
        1.22% of the total cells (4.55% of lymphocytes) are natural killer
        cells (CD3-/CD16&56+).  
        ~
        Clinical and morphologic correlation is recommended.
        ~
        Evaluation is limited by the low viability of the specimen, 48%.
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        This test was developed and its performance characteristics
        determined by the VA San Diego Healthcare System Flow Cytometry
        Laboratory.  It has not been cleared or approved by the FDA.  The
        FDA has determined that such clearance or approval is not
        necessary.  This test is used for clinical purposes.  It should not
        be regarded as investigational or for research.  This laboratory is
        certified under the Clinical Laboratory Improvement Amendments of
        1988 (CLIA-88) as qualified to perform high complexity clinical
        laboratory testing.  
        ~
        Markers Tested: Kappa, Lambda, CD20, CD5, CD23, CD34, CD103, CD200,
        CD45, CD38, CD19, CD10, CD57, CD1a, CD16&56, CD26, CD8, CD3, CD4,
        CD7 
        ~
        Markers tested but not mentioned are either negative or
        non-contributory 
        ~
===============================================================================
 

Report Released Date/Time: Apr 26, 2024@16:51
Provider: KEMP,SARAH ELEANOR
  Specimen: TISSUE.           FC 0425 31
    Specimen Collection Date: Apr 25, 2024@11:34
      Test name                Result    units      Ref.   range   Site Code
IMMUNOPHENOTYPING           comment                                 [664]
Viability, Immunophenotyping   86.71    %                           [664]
Interpretation Rendered By:Kyle Backer, MD 
                                                                    [664]
FLOW MARKER X19                 YES                                 [664]
Comment: ~For Test: FLOW CYTOMETRY FOR LEUKEMIA/LYMPHOMA
        ~EBUS 11Rs LN
        Interpretation: No monotypic B-cell or aberrant T-cell population
        identified.  
        ~
        Phenotype: N/A
        ~
        Note: Immunophenotypic analysis of a FNA specimen was performed by
        flow cytometry.  
        ~
        Approximately 79% of the total cells are CD45 bright positive with
        low side scatter, consistent with lymphocytes. Approximately 19.67%
        of the total cells (24.90% of lymphocytes) are B-cells (CD19+) with
        no evidence of light chain restriction (kappa:lambda ratio of
        1.26). Approximately 56% of the total cells (70% of lymphocytes)
        are T-cells (CD3+) with a CD4:CD8 ratio of 8.30. Approximately
        1.74% of the total cells (2.17% of lymphocytes) are natural killer
        cells (CD3-/CD16&56+).  
        ~
        Clinical and morphologic correlation is recommended.
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        This test was developed and its performance characteristics
        determined by the VA San Diego Healthcare System Flow Cytometry
        Laboratory.  It has not been cleared or approved by the FDA.  The
        FDA has determined that such clearance or approval is not
        necessary.  This test is used for clinical purposes.  It should not
        be regarded as investigational or for research.  This laboratory is
        certified under the Clinical Laboratory Improvement Amendments of
        1988 (CLIA-88) as qualified to perform high complexity clinical
        laboratory testing.  
        ~
        Markers Tested: Kappa, Lambda, CD20, CD5, CD23, CD34, CD103, CD200,
        CD45, CD38, CD19, CD10, CD57, CD1a, CD16&56, CD26, CD8, CD3, CD4,
        CD7 
        ~
        Markers tested but not mentioned are either negative or
        non-contributory 
        ~
===============================================================================
 

Report Released Date/Time: Apr 26, 2024@16:52
Provider: KEMP,SARAH ELEANOR
  Specimen: TISSUE.           FC 0425 32
    Specimen Collection Date: Apr 25, 2024@11:22
      Test name                Result    units      Ref.   range   Site Code
IMMUNOPHENOTYPING           comment                                 [664]
Viability, Immunophenotyping   91.80    %                           [664]
Interpretation Rendered By:Kyle Backer, MD 
                                                                    [664]
FLOW MARKER X19                 YES                                 [664]
Comment: ~For Test: FLOW CYTOMETRY FOR LEUKEMIA/LYMPHOMA
        ~EBUS 11L LN
        Interpretation: No monotypic B-cell or aberrant T-cell population
        identified.  
        ~
        Phenotype: N/A
        ~
        Note: Immunophenotypic analysis of a FNA specimen was performed by
        flow cytometry.  
        ~
        Approximately 92% of the total cells are CD45 bright positive with
        low side scatter, consistent with lymphocytes. Approximately 13.20%
        of the total cells (14.33% of lymphocytes) are B-cells (CD19+) with
        no evidence of light chain restriction (kappa:lambda ratio of
        1.31). Approximately 76% of the total cells (84% of lymphocytes)
        are T-cells (CD3+) with a CD4:CD8 ratio of 9.96. Approximately
        1.14% of the total cells (1.27% of lymphocytes) are natural killer
        cells (CD3-/CD16&56+).  
        ~
        Clinical and morphologic correlation is recommended.
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        ~
         
        This test was developed and its performance characteristics
        determined by the VA San Diego Healthcare System Flow Cytometry
        Laboratory.  It has not been cleared or approved by the FDA.  The
        FDA has determined that such clearance or approval is not
        necessary.  This test is used for clinical purposes.  It should not
        be regarded as investigational or for research.  This laboratory is
        certified under the Clinical Laboratory Improvement Amendments of
        1988 (CLIA-88) as qualified to perform high complexity clinical
        laboratory testing.  
        ~
        Markers Tested: Kappa, Lambda, CD20, CD5, CD23, CD34, CD103, CD200,
        CD45, CD38, CD19, CD10, CD57, CD1a, CD16&56, CD26, CD8, CD3, CD4,
        CD7 
        ~
        Markers tested but not mentioned are either negative or
        non-contributory 
        ~
===============================================================================
 

Report Released Date/Time: Apr 25, 2024@10:47
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0425 87
    Specimen Collection Date: Apr 25, 2024@10:42
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 127 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:188166, Serial Number:UU14386715
===============================================================================
 

Report Released Date/Time: Apr 25, 2024@06:33
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0425 28
    Specimen Collection Date: Apr 25, 2024@06:05
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 121 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:488168, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 25, 2024@08:34
Provider: MOINI ZANDI,TARLAN
  Specimen: SERUM.            CH 0425 32
    Specimen Collection Date: Apr 25, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    134 L   mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.4 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  104     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             23 L   mMol/L     24 - 31          [664]
BUN                              15     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.25 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       32 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           119 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.6 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.2     mg/dL      2.5 - 4.7        [664]
AGAP                              7     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.8     mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.6     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 25, 2024@08:12
Provider: MOINI ZANDI,TARLAN
  Specimen: BLOOD.            HE 0425 30
    Specimen Collection Date: Apr 25, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.40     K/uL       4.60 - 10.10     [664]
RBC                            3.39 L   M/uL       4.30 - 5.80      [664]
HGB                             9.8 L   g/dL       12.4 - 17.4      [664]
HCT                            29.1 L   %          38.0 - 52.0      [664]
MCV                            85.8     fL         80.0 - 100.0     [664]
MCH                            28.9     pg         26.0 - 32.0      [664]
MCHC                           33.7     g/dL       31.0 - 35.0      [664]
RDW-SD                         38.0     fL         35.1 - 46.3      [664]
RDW-CV                         12.0     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             364     K/uL       140 - 400        [664]
MPV                             9.3     fL         9.1 - 12.5       [664]
SEGS %                         59.4     %          45.0 - 70.0      [664]
LYMPHS %                       21.7     %          16.0 - 44.0      [664]
MONOS %                        16.5 H   %          5.0 - 12.0       [664]
EOSINO %                        1.3     %          0.4 - 7.5        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.4     %          0.1 - 1.1        [664]
SEG #                          3.21     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.17     K/uL       0.73 - 3.44      [664]
MONO #                         0.89     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.07     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@20:40
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0424 267
    Specimen Collection Date: Apr 24, 2024@20:21
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 171 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:488168, Serial Number:UU14386583
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@16:52
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0424 213
    Specimen Collection Date: Apr 24, 2024@16:51
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 118 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:645673, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@11:54
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0424 141
    Specimen Collection Date: Apr 24, 2024@11:52
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 197 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735433, Serial Number:UU14386583
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@06:53
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0424 69
    Specimen Collection Date: Apr 24, 2024@06:52
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 128 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:521287, Serial Number:UU14386471
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@08:00
Provider: GU,KELLY MONJIA
  Specimen: SERUM.            CH 0424 37
    Specimen Collection Date: Apr 24, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.7     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  106     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             21 L   mMol/L     24 - 31          [664]
BUN                              12     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.25 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       32 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            94     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.5 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.1     mg/dL      2.5 - 4.7        [664]
AGAP                              9     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.7     mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.8     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@07:58
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            HE 0424 29
    Specimen Collection Date: Apr 24, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                            6.02     K/uL       4.60 - 10.10     [664]
RBC                            3.52 L   M/uL       4.30 - 5.80      [664]
HGB                            10.1 L   g/dL       12.4 - 17.4      [664]
HCT                            30.3 L   %          38.0 - 52.0      [664]
MCV                            86.1     fL         80.0 - 100.0     [664]
MCH                            28.7     pg         26.0 - 32.0      [664]
MCHC                           33.3     g/dL       31.0 - 35.0      [664]
RDW-SD                         38.6     fL         35.1 - 46.3      [664]
RDW-CV                         12.2     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             386     K/uL       140 - 400        [664]
MPV                             9.5     fL         9.1 - 12.5       [664]
SEGS %                         63.5     %          45.0 - 70.0      [664]
LYMPHS %                       20.8     %          16.0 - 44.0      [664]
MONOS %                        13.6 H   %          5.0 - 12.0       [664]
EOSINO %                        1.0     %          0.4 - 7.5        [664]
BASO %                          0.8     %          0.0 - 1.0        [664]
IG %                            0.3     %          0.1 - 1.1        [664]
SEG #                          3.82     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.25     K/uL       0.73 - 3.44      [664]
MONO #                         0.82     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.06     K/uL       0.01 - 0.57      [664]
BASO #                         0.05     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@19:54
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0423 349
    Specimen Collection Date: Apr 23, 2024@19:50
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 153 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735369, Serial Number:UU14386471
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@16:55
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0423 311
    Specimen Collection Date: Apr 23, 2024@16:53
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  92     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:778864, Serial Number:UU14386583
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@11:46
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0423 171
    Specimen Collection Date: Apr 23, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  99     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:778864, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@06:34
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            AT 0423 53
    Specimen Collection Date: Apr 23, 2024@06:33
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 102 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:500281, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@08:15
Provider: GU,KELLY MONJIA
  Specimen: SERUM.            CH 0423 34
    Specimen Collection Date: Apr 23, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.3 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  106     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             19 L   mMol/L     24 - 31          [664]
BUN                               9     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.93 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       39 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            96     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.0     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.6     mg/dL      2.5 - 4.7        [664]
AGAP                             11     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.8     mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.7     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@07:51
Provider: GU,KELLY MONJIA
  Specimen: BLOOD.            HE 0423 33
    Specimen Collection Date: Apr 23, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.14     K/uL       4.60 - 10.10     [664]
RBC                            3.26 L   M/uL       4.30 - 5.80      [664]
HGB                             9.5 L   g/dL       12.4 - 17.4      [664]
HCT                            28.0 L   %          38.0 - 52.0      [664]
MCV                            85.9     fL         80.0 - 100.0     [664]
MCH                            29.1     pg         26.0 - 32.0      [664]
MCHC                           33.9     g/dL       31.0 - 35.0      [664]
RDW-SD                         38.4     fL         35.1 - 46.3      [664]
RDW-CV                         12.1     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             358     K/uL       140 - 400        [664]
MPV                             9.5     fL         9.1 - 12.5       [664]
SEGS %                         64.9     %          45.0 - 70.0      [664]
LYMPHS %                       19.3     %          16.0 - 44.0      [664]
MONOS %                        13.8 H   %          5.0 - 12.0       [664]
EOSINO %                        1.0     %          0.4 - 7.5        [664]
BASO %                          0.8     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.34     K/uL       2.24 - 6.46      [664]
LYMPH #                        0.99     K/uL       0.73 - 3.44      [664]
MONO #                         0.71     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.05     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@21:08
Provider: GU,KELLY MONJIA
  Specimen: URINE.            CH 0422 1221
    Specimen Collection Date: Apr 22, 2024@20:10
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE         <12     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       canc     mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       2.2 H   mg/dL      0.0 - 2.0        [664]
Comment: CANNOT CALCULATE RATIO DUE TO LESS THAN CREAT.RESULT 
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@20:09
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0422 272
    Specimen Collection Date: Apr 22, 2024@20:06
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 130 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735369, Serial Number:UU14386471
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@17:09
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0422 234
    Specimen Collection Date: Apr 22, 2024@17:07
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 121 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735360, Serial Number:UU14386583
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@12:42
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0422 160
    Specimen Collection Date: Apr 22, 2024@12:40
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 107 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735360, Serial Number:UU14386471
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@06:43
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0422 41
    Specimen Collection Date: Apr 22, 2024@06:34
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 112 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735369, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@09:12
Provider: MITTAL,NIKITA
  Specimen: SERUM.            CH 0422 45
    Specimen Collection Date: Apr 22, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.2 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  107 H   mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             21 L   mMol/L     24 - 31          [664]
BUN                               9     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.84 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       41 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           102 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.8     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.4 L   mg/dL      2.5 - 4.7        [664]
AGAP                              9     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.7     mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.3     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        Calcium confirmed by repeat testing. 
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@07:44
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            HE 0422 48
    Specimen Collection Date: Apr 22, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.65     K/uL       4.60 - 10.10     [664]
RBC                            2.97 L   M/uL       4.30 - 5.80      [664]
HGB                             8.5 L   g/dL       12.4 - 17.4      [664]
HCT                            25.6 L   %          38.0 - 52.0      [664]
MCV                            86.2     fL         80.0 - 100.0     [664]
MCH                            28.6     pg         26.0 - 32.0      [664]
MCHC                           33.2     g/dL       31.0 - 35.0      [664]
RDW-SD                         38.4     fL         35.1 - 46.3      [664]
RDW-CV                         12.1     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             325     K/uL       140 - 400        [664]
MPV                             9.3     fL         9.1 - 12.5       [664]
SEGS %                         67.6     %          45.0 - 70.0      [664]
LYMPHS %                       16.6     %          16.0 - 44.0      [664]
MONOS %                        13.5 H   %          5.0 - 12.0       [664]
EOSINO %                        1.6     %          0.4 - 7.5        [664]
BASO %                          0.5     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.82     K/uL       2.24 - 6.46      [664]
LYMPH #                        0.94     K/uL       0.73 - 3.44      [664]
MONO #                         0.76     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.09     K/uL       0.01 - 0.57      [664]
BASO #                         0.03     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 21, 2024@19:39
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0421 182
    Specimen Collection Date: Apr 21, 2024@19:36
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 157 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735369, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 21, 2024@16:55
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0421 148
    Specimen Collection Date: Apr 21, 2024@16:53
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 181 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735360, Serial Number:UU14386471
===============================================================================
 

Report Released Date/Time: Apr 21, 2024@12:03
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0421 86
    Specimen Collection Date: Apr 21, 2024@11:51
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 119 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735360, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 21, 2024@06:28
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0421 21
    Specimen Collection Date: Apr 21, 2024@06:18
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  97     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:488168, Serial Number:UU14386583
===============================================================================
 

Report Released Date/Time: Apr 21, 2024@08:20
Provider: SMITH,MARGARET ELAINE
  Specimen: BLOOD.            HE 0421 11
    Specimen Collection Date: Apr 21, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.56     K/uL       4.60 - 10.10     [664]
RBC                            3.13 L   M/uL       4.30 - 5.80      [664]
HGB                             9.2 L   g/dL       12.4 - 17.4      [664]
HCT                            27.3 L   %          38.0 - 52.0      [664]
MCV                            87.2     fL         80.0 - 100.0     [664]
MCH                            29.4     pg         26.0 - 32.0      [664]
MCHC                           33.7     g/dL       31.0 - 35.0      [664]
RDW-SD                         40.0     fL         35.1 - 46.3      [664]
RDW-CV                         12.5     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             354     K/uL       140 - 400        [664]
MPV                             9.5     fL         9.1 - 12.5       [664]
SEGS %                         66.8     %          45.0 - 70.0      [664]
LYMPHS %                       18.3     %          16.0 - 44.0      [664]
MONOS %                        12.4 H   %          5.0 - 12.0       [664]
EOSINO %                        1.6     %          0.4 - 7.5        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.71     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.02     K/uL       0.73 - 3.44      [664]
MONO #                         0.69     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.09     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 21, 2024@08:54
Provider: SMITH,MARGARET ELAINE
  Specimen: SERUM.            CH 0421 25
    Specimen Collection Date: Apr 21, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.5     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  101     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                              15     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.08 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       35 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            88     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            11.0 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.7     mg/dL      2.5 - 4.7        [664]
AGAP                             11     mMol/L     6 - 15           [664]
AST                              36 H   IU/L       10 - 35          [664]
ALT                              21     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             85     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.7     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.6     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@20:03
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0420 207
    Specimen Collection Date: Apr 20, 2024@19:54
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 117 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:488168, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@16:43
Provider: MITTAL,NIKITA
  Specimen: BLOOD.            AT 0420 165
    Specimen Collection Date: Apr 20, 2024@16:42
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 122 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:797000, Serial Number:UU14386706
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@17:34
Provider: MITTAL,NIKITA
  Specimen: URINE.            CH 0420 273
    Specimen Collection Date: Apr 20, 2024@16:20
      Test name                Result    units      Ref.   range   Site Code
PROTEIN, URINE                   12     mg/dL                       [664]
CREATININE, URINE             <12.0     mg/dL                       [664]
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@11:36
Provider: SMITH,MARGARET ELAINE
  Specimen: BLOOD.            AT 0420 79
    Specimen Collection Date: Apr 20, 2024@11:34
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  99     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735374, Serial Number:UU14386471
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@11:17
Provider: LOVETRO,BLAINE K
  Specimen: BLOOD.            HE 0420 87
    Specimen Collection Date: Apr 20, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.51     K/uL       4.60 - 10.10     [664]
RBC                            2.93 L   M/uL       4.30 - 5.80      [664]
HGB                             8.6 L   g/dL       12.4 - 17.4      [664]
HCT                            25.8 L   %          38.0 - 52.0      [664]
MCV                            88.1     fL         80.0 - 100.0     [664]
MCH                            29.4     pg         26.0 - 32.0      [664]
MCHC                           33.3     g/dL       31.0 - 35.0      [664]
RDW-SD                         40.9     fL         35.1 - 46.3      [664]
RDW-CV                         12.6     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             330     K/uL       140 - 400        [664]
MPV                             9.3     fL         9.1 - 12.5       [664]
SEGS %                         63.0     %          45.0 - 70.0      [664]
LYMPHS %                       20.3     %          16.0 - 44.0      [664]
MONOS %                        13.6 H   %          5.0 - 12.0       [664]
EOSINO %                        2.2     %          0.4 - 7.5        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.47     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.12     K/uL       0.73 - 3.44      [664]
MONO #                         0.75     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.12     K/uL       0.01 - 0.57      [664]
BASO #                         0.04     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@11:34
Provider: LOVETRO,BLAINE K
  Specimen: SERUM.            CH 0420 132
    Specimen Collection Date: Apr 20, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.9     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  107 H   mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             22 L   mMol/L     24 - 31          [664]
BUN                              14     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.09 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       35 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            95     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            11.8 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.2 L   mg/dL      2.5 - 4.7        [664]
AGAP                              8     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.7     mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.4     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@06:28
Provider: SMITH,MARGARET ELAINE
  Specimen: BLOOD.            AT 0420 23
    Specimen Collection Date: Apr 20, 2024@06:14
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  90     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:488168, Serial Number:UU14386583
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@14:49
Provider: KOETT,JAMIE LOUISE
  Specimen: SERUM.            IM 0419 309
    Specimen Collection Date: Apr 19, 2024@22:47
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            18.8 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Apr 20, 2024@02:08
Provider: KOETT,JAMIE LOUISE
  Specimen: PLASMA.           CH 0419 1114
    Specimen Collection Date: Apr 19, 2024@22:47
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                          <6 L   pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@23:02
Provider: KOETT,JAMIE LOUISE
  Specimen: URINE.            UA 0419 189
    Specimen Collection Date: Apr 19, 2024@22:21
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                 SL. CLOUDY                               [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.008                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: <NEGATIVE   [664]
NITRITE, URINE             NEGATIVE                Ref: <NEGATIVE   [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                      1+ H              Ref: <NEGATIVE   [664]
UR PROTEIN                       1+ H              Ref: <NEGATIVE   [664]
URINE GLUCOSE              NEGATIVE                Ref: <NEGATIVE   [664]
URINE KETONES              NEGATIVE                Ref: <NEGATIVE   [664]
UROBILINOGEN,URINE             <2.0     mg/dL      Ref: <=2.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: <NEGATIVE   [664]
WBC/HPF                       11-20 H   /HPF       0 - 2            [664]
RBC/HPF                         0-2     /HPF       0 - 2            [664]
BACTERIA                       RARE     /HPF                        [664]
URINE YEAST                     FEW     /HPF                        [664]
Comment: Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@22:08
Provider: KOETT,JAMIE LOUISE
  Specimen: NARES.            IDS 24 8271
    Specimen Collection Date: Apr 19, 2024@20:38
      Test name                Result    units      Ref.   range   Site Code
MRSA SURVL NARES DNA       Negative                Ref: Negative    [664]
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@21:32
Provider: KOETT,JAMIE LOUISE
  Specimen: NASOPHARYNX.      SOMI 0419 43
    Specimen Collection Date: Apr 19, 2024@20:38
      Test name                Result    units      Ref.   range   Site Code
INFLUENZA A SCREEN         Negative                Ref: Negative    [664]
INFLUENZA B SCREEN         Negative                Ref: Negative    [664]
      Eval: Influenza A and B testing performed by molecular (PCR) testing.
COVID-19 RNA               Not Detected 
                                                   Ref: Not Detected
                                                                    [664]
Respiratory Syncytial VirusNegative                Ref: Negative    [664]
Comment: ~Symptomatic (Admission ONLY)
        Negative results do not exclude 2019-nCoV infection and should not
        be used as the sole basis for treatment or other patient management
        decisions. If diagnosis will affect management then it may be
        necessary to collect multiple specimens to detect the virus.  
        Results were obtained using the Cepheid Infinity Xpert
        SARS-CoV-2/Flu/RSV Assay, testing completed at VA San Diego HCS
        (664).  
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@23:39
Provider: KOETT,JAMIE LOUISE
  Specimen: SERUM.            CH 0419 1113
    Specimen Collection Date: Apr 19, 2024@20:15
      Test name                Result    units      Ref.   range   Site Code
THYROID STIMULATING HORMONE    2.34     mIU/L      0.49 - 4.67      [664]
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@21:09
Provider: KOETT,JAMIE LOUISE
  Specimen: SERUM.            CH 0419 1079
    Specimen Collection Date: Apr 19, 2024@20:15
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    132 L   mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.2 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  101     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             21 L   mMol/L     24 - 31          [664]
BUN                              16     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.25 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       32 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           102 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            12.2 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.9     mg/dL      2.5 - 4.7        [664]
AGAP                             10     mMol/L     6 - 15           [664]
AST                              34     IU/L       10 - 35          [664]
ALT                              19     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             82     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.5     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.6     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@20:43
Provider: KOETT,JAMIE LOUISE
  Specimen: BLOOD.            HE 0419 503
    Specimen Collection Date: Apr 19, 2024@20:15
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.49     K/uL       4.60 - 10.10     [664]
RBC                            3.05 L   M/uL       4.30 - 5.80      [664]
HGB                             9.1 L   g/dL       12.4 - 17.4      [664]
HCT                            27.2 L   %          38.0 - 52.0      [664]
MCV                            89.2     fL         80.0 - 100.0     [664]
MCH                            29.8     pg         26.0 - 32.0      [664]
MCHC                           33.5     g/dL       31.0 - 35.0      [664]
RDW-SD                         41.5     fL         35.1 - 46.3      [664]
RDW-CV                         12.7     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             342     K/uL       140 - 400        [664]
MPV                             9.3     fL         9.1 - 12.5       [664]
SEGS %                         59.3     %          45.0 - 70.0      [664]
LYMPHS %                       22.6     %          16.0 - 44.0      [664]
MONOS %                        13.5 H   %          5.0 - 12.0       [664]
EOSINO %                        3.1     %          0.4 - 7.5        [664]
BASO %                          1.1 H   %          0.0 - 1.0        [664]
IG %                            0.4     %          0.1 - 1.1        [664]
SEG #                          3.26     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.24     K/uL       0.73 - 3.44      [664]
MONO #                         0.74     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.17     K/uL       0.01 - 0.57      [664]
BASO #                         0.06     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 19, 2024@16:31
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            CH 0419 431
    Specimen Collection Date: Apr 19, 2024@09:58
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.8     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  104     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             22 L   mMol/L     24 - 31          [664]
BUN                              17     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.28 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       32 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           104 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            12.9 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.4 L   mg/dL      2.5 - 4.7        [664]
AGAP                             11     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   3.7     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 24, 2024@07:22
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            CH 0419 336
    Specimen Collection Date: Apr 19, 2024@09:23
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                   canc     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                canc     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                 canc     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL           canc     mMol/L     24 - 31          [664]
BUN                            canc     mg/dL      8 - 23           [664]
CREATININE LEVEL               canc     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)     canc                Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM          canc     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            canc     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL               canc     mg/dL      2.5 - 4.7        [664]
AGAP                           canc     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                canc     mg/dL      1.6 - 2.5        [664]
AST                            canc     IU/L       10 - 35          [664]
ALT                            canc     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE           canc     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                canc     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                  canc     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        Notified by RN of mislabeled specimen after resulting. 
        Results confirmned by repeat testing. 
        Unable to determine specimen integrety due to mislabel of specimen. 
        Test results cancelled. 
        Notified Dr. Moininezandi of test cancellation @ 07:14 4/24/24 ww 
        GLUCOSE reported incorrectly as 94 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        CREATININE reported incorrectly as 1.24 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        SODIUM reported incorrectly as 134 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        SODIUM flagged incorrectly as L by [687589-VA664].
        Abnormal flag removed on Apr 24, 2024@07:22 by [406562-VA664].
        CHLORIDE reported incorrectly as 101 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        MAGNESIUM reported incorrectly as 2.1 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        PO4 reported incorrectly as 3.1 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        POTASSIUM reported incorrectly as 3.9 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        HCO3 reported incorrectly as 28 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        CALCIUM reported incorrectly as 9.2 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        ALANINE AMINOTRANSFERASE reported incorrectly as 19 by
        [687589-VA664].  
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        ASPARTATE AMINOTRANSFERASE reported incorrectly as 20 by
        [687589-VA664].  
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        ALKALINE PHOSPHATASE reported incorrectly as 47 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        UREA NITROGEN reported incorrectly as 18 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        ALBUMIN reported incorrectly as 3.9 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        TOTAL BILIRUBIN reported incorrectly as 0.6 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        EGFR (RENAL) reported incorrectly as 66 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        ANION GAP reported incorrectly as 5 by [687589-VA664].
        Changed to canc on Apr 24, 2024@07:22 by [406562-VA664].
        ANION GAP flagged incorrectly as L by [687589-VA664].
        Abnormal flag removed on Apr 24, 2024@07:22 by [406562-VA664].
===============================================================================
 

Report Released Date/Time: Apr 26, 2024@06:31
Provider: CHEN,KAY JIE
  Specimen: FECES.            NIC 0419 437
    Specimen Collection Date: Apr 19, 2024@08:30
      Test name                Result    units      Ref.   range   Site Code
CALPROTECTIN, STOOL             552 H   mcg/g                       [73367]
Comment: Calprotectin, Stool
                                              Reference Range:
                                              <50     Normal
                                              50-120  Borderline
                                              >120    Elevated
         
        Calprotectin in Crohn's disease and ulcerative colitis can
        be five to several thousand times above the reference
        population (50 mcg/g or less). Levels are usually 50 mcg/g
        or less in healthy patients and with irritable bowel
        syndrome. Repeat testing in 4-6 weeks is suggested for
        borderline values.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Apr 29, 2024@06:48
Provider: CHEN,KAY JIE
  Specimen: FECES.            NIC 0419 435
    Specimen Collection Date: Apr 19, 2024@08:30
      Test name                Result    units      Ref.   range   Site Code
PANCREATIC ELASTASE-1, STOOL     <15 L  mcg/g                       [73367]
Comment: Pancreatic Elastase-1
         
        Adult and Pediatric Reference Ranges for
          Pancreatic Elastase-1:
         
                     Normal:      >200 mcg/g
        Moderate Pancreatic
              Insufficiency:   100-200 mcg/g
          Severe Pancreatic
              Insufficiency:      <100 mcg/g
         
        Elastase-1 (E-1) assay results are expressed
        in mcg/g, which represent mcg E1/g feces.
         
        It is not necessary to interrupt enzyme
        substitution therapy.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Apr 25, 2024@06:55
Provider: CHEN,KAY JIE
  Specimen: FECES.            NIC 0419 431
    Specimen Collection Date: Apr 19, 2024@08:30
      Test name                Result    units      Ref.   range   Site Code
FECAL FAT, QUALITATIVE       NORMAL                Ref: NORMAL      [73367]
Comment: TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Jun 30, 2025@14:47
Provider: NEELEY,EUNICE ELIZABETH
  Specimen: FECES.            STOOL 25 6535
    Specimen Collection Date: Jun 25, 2025@09:00
      Test name                Result    units      Ref.   range   Site Code
OCCULT BLOOD (FIT) #1 OF 1 Negative                Ref: Negative    [664]
      Eval: FIT is an immunological test developed to detect human globin - the 
      Eval: protein part of hemoglobin - it is specific for bleeding from the distal 
      Eval: gut. Negative results for the immunological test do not assure absence of 
      Eval: GI bleeding or pathology. Gastrointestinal lesions may bleed 
      Eval: intermittently and blood in feces is not distributed evenly. This 
      Eval: screening is not intended to replace other diagnostic procedures such as 
      Eval: colonoscopy or sigmoidoscopy in combination with double contrast barium 
      Eval: x-rays, and is not intended for patients with upper GI bleeds. Bowel 
      Eval: lesions, including some polyps and colorectal cancers may not bleed at all
      Eval: or bleed intermittently.
===============================================================================


Report Released Date/Time: Apr 15, 2024@16:03
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            CH 0415 1108
    Specimen Collection Date: Apr 15, 2024@13:41
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.9     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  106     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             20 L   mMol/L     24 - 31          [664]
BUN                              16     mg/dL      8 - 23           [664]
CREATININE LEVEL               2.20 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       33 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            61 L   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            12.8 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.7     mg/dL      2.5 - 4.7        [664]
AGAP                             11     mMol/L     6 - 15           [664]
AST                              36 H   IU/L       10 - 35          [664]
ALT                              21     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             85     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.5     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.7     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Apr 23, 2024@06:18
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 0415 683
    Specimen Collection Date: Apr 15, 2024@13:40
      Test name                Result    units      Ref.   range   Site Code
COPPER, SERUM                   125     mcg/dL     70 - 175         [73367]
Comment: (Note)
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by the FDA. This assay
        has been validated pursuant to the CLIA regulations and is
        used for clinical purposes.
         
        MDF
        med fusion
        2501 South State Highway 121,Suite 1100
        Lewisville TX 75067
        972-966-7300
        Ithiel James L. Frame, MD, PhD
        TEST PERFORMED AT:
        MedFusion
        2501 South State Highway 121, Suite 1100
        Lewisville, TX 75067-8188
        Director: I J Frame MD, PhD
===============================================================================
 

Report Released Date/Time: Apr 22, 2024@06:55
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 0415 681
    Specimen Collection Date: Apr 15, 2024@13:40
      Test name                Result    units      Ref.   range   Site Code
ERYTHROPOIETIN                  5.9     mIU/mL     2.6 - 18.5       [73367]
Comment: ~For Test: B12/FOLATE
        ~please draw in addition to all labs dated 2/2/2024, thanks
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Apr 15, 2024@15:54
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0415 1107
    Specimen Collection Date: Apr 15, 2024@13:40
      Test name                Result    units      Ref.   range   Site Code
VITAMIN B12 LEVEL             >1200 H   pg/mL      210 - 1020       [664]
FOLATE LEVEL                    8.2     ng/mL      4.0 - 20         [664]
Comment: ~For Test: B12/FOLATE
        ~please draw in addition to all labs dated 2/2/2024, thanks
        FOL:
        Taking unusually large doses of biotin can interfere with this
        immunoassay test results. Biotin has a very short half-life and it
        is cleared within 12 hours. Patients should not take Biotin
        supplements the day of a specimen collection.  
===============================================================================
 

Report Released Date/Time: Apr 08, 2024@07:43
Provider: WEI,JENNIE H
  Specimen: PLASMA.           NIC 0402 239
    Specimen Collection Date: Apr 02, 2024@11:09
      Test name                Result    units      Ref.   range   Site Code
VITAMIN K1                      308     pg/mL      130 - 1500       [73367]
Comment:  
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics Nichols Institute Chantilly, VA. It has
        not been cleared or approved by the U.S. Food and Drug
        Administration. This assay has been validated pursuant
        to the CLIA regulations and is used for clinical
        purposes.
         
        TEST PERFORMED AT:
        Quest Diagnostics/Nichols Chantilly
        14225 Newbrook Dr
        Chantilly, VA 20151-2228
        Director: P W Mason MD, PhD
===============================================================================
 

Report Released Date/Time: Apr 15, 2024@06:58
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 0402 238
    Specimen Collection Date: Apr 02, 2024@11:09
      Test name                Result    units      Ref.   range   Site Code
RETINOL                          55     mcg/dL     38 - 98          [73367]
Alpha-Tocopherol (Vit E)       16.3     mg/L                        [73367]
gToco                           1.2     mg/L       Ref: <=4.4       [73367]
Comment: Vit E, Alpha Tocopherol
              Reference Range
              5.7-19.9 mg/L
         
              Levels of alpha-tocopherol <5 mg/L are
              consistent with Vitamin E deficiency in
              adults.
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA 91355-5386
        Director: T McDonald MD
        **Clin Chem Vol. 34.No.8. pp1625-1628. 1998
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA 91355-5386
        Director: T McDonald MD
===============================================================================
 

Report Released Date/Time: 
Provider: WEI,JENNIE H
  Specimen: SERUM.            IM 0402 206
    Specimen Collection Date: Apr 02, 2024@11:09
      Test name                Result    units      Ref.   range   Site Code
VIT D25                    Test Not Performed 
Comment: *VITAMIN D (25,HYDROXY) TOTAL PANEL Not Performed: Apr 02, 2024@11:1
        *NP Reason: DUPE REF> IM 0402 192
===============================================================================
 

Report Released Date/Time: Apr 15, 2024@06:58
Provider: WEI,JENNIE H
  Specimen: PLASMA.           NIC 0402 237
    Specimen Collection Date: Apr 02, 2024@11:09
      Test name                Result    units      Ref.   range   Site Code
PTHrP CLINICAL                   11     pg/mL      11 - 20          [73367]
Comment:  
        This is a C-terminal PTH-RP assay. PTH-RP is useful in the
        differential diagnosis of hypercalcemia and levels may be
        elevated in patients with tumor-associated hypercalcemia.
        Elevated results may also be observed in patients with renal
        disease.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by FDA. This assay has
        been validated pursuant to the CLIA regulations and is used
        for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Apr 17, 2024@06:38
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 0402 229
    Specimen Collection Date: Apr 02, 2024@11:09
      Test name                Result    units      Ref.   range   Site Code
Vitamin D3, 1,25 (OH)2           88     pg/mL      Ref: NO REFERENCE RANGE
                                                                    [73367]
Vitamin D2, 1,25 (OH)2           <8     pg/mL      Ref: NO REFERENCE RANGE
                                                                    [73367]
1,25-DI                          88 H   pg/mL      18 - 72          [73367]
Comment: Vitamin D,1,25 (OH)2,Total
         
        Reference Ranges for Vitamin D, 1,25 (OH)2, Total  pg/mL
         
               < 1 Year   Not established
              1-9 Years   31-87
            10-13 Years   30-83
            14-17 Years   19-83
        > or = 18 Years   18-72
         
        Vitamin D3, 1,25(OH)2 indicates both endogenous production
        and supplementation. Vitamin D2, 1,25(OH)2 is an indicator
        of exogenous sources, such as diet or supplementation.
        Interpretation and therapy are based on measurement of
        Vitamin D, 1,25 (OH)2, Total.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by FDA. This assay has
        been validated pursuant to the CLIA regulations and is used
        for clinical purposes.
         
        For additional information, please refer to
        http://education.QuestDiagnostics.com/faq/FAQ199
        (This link is being provided for informational/educational
        purposes only.)
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: 
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0402 344
    Specimen Collection Date: Apr 02, 2024@11:09
      Test name                Result    units      Ref.   range   Site Code
Comment: *CBC Not Performed: Apr 02, 2024@11:31 by 489556
        *NP Reason: REF TO HE 341
        *RETICULOCYTE PANEL Not Performed: Apr 02, 2024@11:31 by 489556
        *NP Reason: REF TO HE 341
===============================================================================
 

Report Released Date/Time: Apr 08, 2024@07:42
Provider: CHEN,KAY JIE
  Specimen: SERUM.            NIC 0402 222
    Specimen Collection Date: Apr 02, 2024@11:08
      Test name                Result    units      Ref.   range   Site Code
CAROTENE, SERUM                  <2 L   mcg/dL     4 - 51           [73367]
Comment:  
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of the results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics Nichols Institute Chantilly, VA. It has
        not been cleared or approved by the U.S. Food and Drug
        Administration. This assay has been validated pursuant
        to the CLIA regulations and is used for clinical
        purposes.
         
        TEST PERFORMED AT:
        Quest Diagnostics/Nichols Chantilly
        14225 Newbrook Dr
        Chantilly, VA 20151-2228
        Director: P W Mason MD, PhD
===============================================================================
 

Report Released Date/Time: Apr 03, 2024@10:56
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0402 193
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  5.2     %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        http://www.ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Apr 12, 2024@07:52
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            LEX 0402 1
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
ASPERGILLUS-CF             NEGATIVE                Ref: NEGATIVE    [596]
ASPERGILLUS-ID             NOT INDICATED 
                                                   Ref: NEGATIVE    [596]
BLASTOMYCES-CF             NEGATIVE                Ref: NEGATIVE    [596]
BLASTOMYCES-ID             NOT INDICATED 
                                                   Ref: NEGATIVE    [596]
COCC. IMMITIS-CF           NEGATIVE                Ref: NEGATIVE    [596]
COCC. IMMITIS-LATEX        NEGATIVE                Ref: NEGATIVE    [596]
COCC. IMMITIS-ID           NEGATIVE                Ref: NEGATIVE    [596]
HISTO CAP. YEAST-CF        NEGATIVE                Ref: NEGATIVE    [596]
HISTO MYCELIAL-CF          NEGATIVE                Ref: NEGATIVE    [596]
HISTO CAPSULATUM ID        NOT INDICATED 
                                                   Ref: NEGATIVE    [596]
Comment: Complement Fixation (CF) starting dilutions for serum
        specimens are 1:2 for C. immitis and 1:8 for all other
        antibodies.  Starting dilutions for CSF are undiluted
        unless otherwise indicated.
         
        Immunodiffusion (ID) Presence of precipitin bands is specific
        for previous or current infection.
        Complement fixation (CF) Serum titers =>1:16 are suggestive
        of systemic infection; titers 1:2 - 1:8 are possibly
        significant of localized disease for C. immitis. In CSF
        samples any titer is potentially significant.
        Latex Agglutination - Positive in early primary cocci
        infection.
        Anticomplementary (AC): Result is indeterminate as there is a
        substance in the patient's specimen interfering with the
        reading of the test.
        "Neg. at" indicates that there is a low level, less than a
        significant CF titer, of anti-complementary activity in the
        patient's sample.  The value reported is the lowest
        dilution showing no anti-complementary activity.
===============================================================================
 

Report Released Date/Time: Apr 03, 2024@08:02
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            SPCH 0402 141
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
zHIV SCR                   Negative                Ref: Negative    [664]
      Eval: As of 10/21/2015, testing for qualitative HIV detection is performed using
      Eval: the FDA approved 4th generation Siemens HIV Ag/Ab Combo (CHIV) assay.  The
      Eval: assay is an in vitro diagnostic immunoassay for the simultaneous
      Eval: qualitative detection of human immunodeficiency virus p24 antigen and
      Eval: antibodies to human immunodeficiency viruses type 1 (including group "O")
      Eval: and type 2.
===============================================================================
 

Report Released Date/Time: 
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: CSF.              NIC 0402 220
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
ADENOSINE DEAMINASE        Test Not Performed 
Comment: *ADENOSINE DEAMINASE Not Performed: Apr 02, 2024@11:41 by 489556
        *NP Reason: ACC IN ERROR REF TO #667962
===============================================================================
 

Report Released Date/Time: Apr 03, 2024@13:45
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: BLOOD.            IM 0402 198
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
Quantiferon Gold TB        Negative                Ref: Negative    [664]
TB MINUS NIL                 0.0120     IU/mL                       [664]
NIL VALUE                    0.4930     IU/mL                       [664]
MITOGEN CONTROL              9.5070     IU/mL                       [664]
TB2 MINUS NIL                0.0120     IU/mL                       [664]
Comment: A Negative result does not preclude the possibility of M.
        tuberculosis infection or tuberculosis disease: false-negative
        results can be due to the stage of infection (e.g., specimen
        obtained prior to the development of cellular immune response or
        other immunological variables).  
===============================================================================
 

Report Released Date/Time: Apr 04, 2024@15:02
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            SEP 0402 9
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
ANA (DIFA)                 NEGATIVE                Ref: NEGATIVE    [68392]
===============================================================================
 

Report Released Date/Time: Apr 02, 2024@14:31
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            IM 0402 192
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            24.5 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Apr 02, 2024@12:22
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: BLOOD.            HE 0402 342
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
ESR                              33 H   mm/hr      0 - 15           [664]
===============================================================================
 

Report Released Date/Time: Apr 02, 2024@12:15
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: BLOOD.            HE 0402 341
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.08     K/uL       4.60 - 10.10     [664]
RBC                            3.07 L   M/uL       4.30 - 5.80      [664]
HGB                             8.8 L   g/dL       12.4 - 17.4      [664]
HCT                            27.0 L   %          38.0 - 52.0      [664]
MCV                            87.9     fL         80.0 - 100.0     [664]
MCH                            28.7     pg         26.0 - 32.0      [664]
MCHC                           32.6     g/dL       31.0 - 35.0      [664]
RDW-SD                         41.5     fL         35.1 - 46.3      [664]
RDW-CV                         12.9     %          11.0 - 15.0      [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                          0.00     K/uL       0.00 - 0.01      [664]
PLT                             345     K/uL       140 - 400        [664]
MPV                             9.5     fL         9.1 - 12.5       [664]
SEGS %                         61.9     %          45.0 - 70.0      [664]
LYMPHS %                       20.9     %          16.0 - 44.0      [664]
MONOS %                        13.8 H   %          5.0 - 12.0       [664]
EOSINO %                        2.2     %          0.4 - 7.5        [664]
BASO %                          1.0     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.1 - 1.1        [664]
SEG #                          3.15     K/uL       2.24 - 6.46      [664]
LYMPH #                        1.06     K/uL       0.73 - 3.44      [664]
MONO #                         0.70     K/uL       0.25 - 0.97      [664]
EOSINO #                       0.11     K/uL       0.01 - 0.57      [664]
BASO #                         0.05     K/uL       0.01 - 0.10      [664]
IG #                          <0.03     K/uL       0.00 - 0.07      [664]
===============================================================================
 

Report Released Date/Time: Apr 10, 2024@06:59
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            NIC 0402 219
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
COPPER, SERUM                   123     mcg/dL     70 - 175         [73367]
Comment: (Note)
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by the FDA. This assay
        has been validated pursuant to the CLIA regulations and is
        used for clinical purposes.
         
        MDF
        med fusion
        2501 South State Highway 121,Suite 1100
        Lewisville TX 75067
        972-966-7300
        Ithiel James L. Frame, MD, PhD
        TEST PERFORMED AT:
        MedFusion
        2501 South State Highway 121, Suite 1100
        Lewisville, TX 75067-8188
        Director: I J Frame MD, PhD
===============================================================================
 

Report Released Date/Time: Apr 12, 2024@07:11
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            NIC 0402 215
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
ANCA                       POSITIVE                Ref: NEGATIVE    [73367]
MYELOPEROXIDASE AB             <1.0     AI         Ref: <=1.0       [73367]
      Eval: PREVIOUS REFERENCE INTERVAL:
      Eval:           Negative:    < 6
      Eval:           Equivocal:   6-9
      Eval:           Positive:    > 9
SERINE PROTEASE 3              <1.0     AI         Ref: <=1.0       [73367]
      Eval: PREVIOUS REFERENCE INTERVAL:
      Eval:           Negative:    < 6
      Eval:           Equivocal:   6-9
      Eval:           Positive:    > 9
ATYPICAL P-ANCA TITER         1:160 H   titer      Ref: <1:20       [73367]
Comment: normalcy status - Abnormal
         
        ANCA Screen includes evaluation for p-ANCA, c-ANCA and
        atypical p-ANCA. A positive ANCA screen reflexes to titer
        and pattern(s), e.g., cytoplasmic pattern (c-ANCA),
        perinuclear pattern (p-ANCA), or atypical p-ANCA pattern.
        c-ANCA and p-ANCA are observed in vasculitis, whereas
        atypical p-ANCA is observed in IBD (Inflammatory Bowel
        Disease). Atypical p-ANCA is detected in about 55% to 80% of
        patients with ulcerative colitis but only 5% to 25% of
        patients with Crohn's disease.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Atypical ANCA was observed.  This pattern has been
        associated with various diseases, including ulcerative
        colitis, Crohn's disease, chronic liver disease, rheumatoid
        arthritis, systemic lupus erythematosis, and on occasion,
        Wegener's Granulomatosis.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
         
              <1.0 AI No Antibody Detected
        > or = 1.0 AI Antibody Detected
         
        Autoantibodies to myeloperoxidase (MPO) are commonly
        associated with the following small-vessel vasculitides:
        microscopic polyangiitis, polyarteritis nodosa,
        Churg-Strauss syndrome, necrotizing and crescentic
        glomerulonephritis and occasionally granulomatosis with
        polyangiitis (GPA, Wegener's). The perinuclear IFA pattern,
        (p-ANCA) is based largely on autoantibody to myeloperoxidase
        which serves as the primary antigen. These autoantibodies
        are present in active disease.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
         
              <1.0 AI No Antibody Detected
        > or = 1.0 AI Antibody Detected
         
        Autoantibodies to proteinase-3 (PR-3) are accepted as
        characteristic for granulomatosis with polyangiitis (GPA,
        Wegener's), and are detectable in 95% of the histologically
        proven cases. The cytoplasmic IFA pattern, (c-ANCA), is
        based largely on autoantibody to PR-3 which serves as the
        primary antigen. These autoantibodies are present in active
        disease.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Apr 10, 2024@06:59
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            NIC 0402 214
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
ERYTHROPOIETIN                 16.6     mIU/mL     2.6 - 18.5       [73367]
ACE                              <5 L   U/L        9 - 67           [73367]
SOLUBLE TRANSFERRIN RECEPTOR    1.79 H  mg/L       0.76 - 1.76      [73367]
Comment: TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Apr 04, 2024@12:17
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            IDS 24 6857
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
COCCI SEROLOGY IgG         NEGATIVE                Ref: Negative    [664]
COCCI SEROLOGY IgM         NEGATIVE                Ref: Negative    [664]
===============================================================================
 

Report Released Date/Time: Apr 02, 2024@12:50
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            CH 0402 643
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
LACTATE DEHYDROGENASE           153     IU/L       Ref: <=190       [664]
===============================================================================
 

Report Released Date/Time: Apr 02, 2024@12:50
Provider: HERRMANN,AMANDA LINDSEY
  Specimen: SERUM.            CH 0402 642
    Specimen Collection Date: Apr 02, 2024@11:07
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.3 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  102     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                              12     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.65 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       47 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           104 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            11.8 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.2     mg/dL      2.5 - 4.7        [664]
AGAP                             10     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.4 L   mg/dL      1.6 - 2.5        [664]
URIC ACID LEVEL                 7.3 H   mg/dL      3.5 - 7.2        [664]
AST                              46 H   IU/L       10 - 35          [664]
ALT                              26     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             72     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.7     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.5     g/dL       3.2 - 4.6        [664]
CRP UltraSens                  1.82 H   mg/dL      Ref: <=0.8       [664]
VITAMIN B12 LEVEL               688     pg/mL      210 - 1020       [664]
Comment:  Added by 676116 on Apr 02, 2024@11:11
        eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: SPMI 24 132 [2424000132]   Received: Apr 02, 2024@11:07
Collection sample: BLOOD-RED(SER)      Collection date: Apr 02, 2024 11:07
Site/Specimen: SERUM
Provider: HERRMANN,AMANDA LINDSEY
Comment on specimen: 1074161 
                                                                               
                                                                               
 Test(s) ordered: CRYPTOCOCCUS ANTIGEN TEST..... completed: Apr 04, 2024 11:14

* BACTERIOLOGY FINAL REPORT => Apr 04, 2024 11:15   TECH CODE: 509555
Bacteriology Remark(s):
  NEGATIVE FOR CYPTOCOCCAL ANTIGEN 
                                                                               
=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--=--
Performing Laboratory:
Bacteriology Report Performed By: 
VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
3350 La Jolla Village Drive San Diego, CA 92161-0002

===============================================================================
 

Report Released Date/Time: Mar 20, 2024@14:50
Provider: CHEN,KAY JIE
  Specimen: SERUM.            CH 0320 948
    Specimen Collection Date: Mar 20, 2024@08:30
      Test name                Result    units      Ref.   range   Site Code
CREATINE KINASE                  70     IU/L       0 - 175          [664]
===============================================================================
 

Report Released Date/Time: Mar 20, 2024@13:49
Provider: CHEN,KAY JIE
  Specimen: BLOOD.            HE 0320 152
    Specimen Collection Date: Mar 20, 2024@08:26
      Test name                Result    units      Ref.   range   Site Code
WBC                            5.03     K/uL       4.60 - 10.10     [664]
RBC                            3.07 L   M/uL       4.30 - 5.80      [664]
HGB                             8.9 L   g/dL       12.4 - 17.4      [664]
HCT                            26.9 L   %          38.0 - 52.0      [664]
MCV                            87.6     fL         80.0 - 100.0     [664]
MCH                            29.0     pg         26.0 - 32.0      [664]
MCHC                           33.1     g/dL       31.0 - 35.0      [664]
RDW-SD                         43.8     fL         35.1 - 46.3      [664]
RDW-CV                         13.6     %          11.0 - 15.0      [664]
PLT                             371     K/uL       140 - 400        [664]
MPV                            10.0     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Mar 28, 2024@06:48
Provider: CHEN,KAY JIE
  Specimen: SERUM.            NIC 0320 48
    Specimen Collection Date: Mar 20, 2024@08:26
      Test name                Result    units      Ref.   range   Site Code
CAROTENE, SERUM                  <2 L   mcg/dL     4 - 51           [73367]
Comment:  
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of the results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics Nichols Institute Chantilly, VA. It has
        not been cleared or approved by the U.S. Food and Drug
        Administration. This assay has been validated pursuant
        to the CLIA regulations and is used for clinical
        purposes.
         
        TEST PERFORMED AT:
        Quest Diagnostics/Nichols Chantilly
        14225 Newbrook Dr
        Chantilly, VA 20151-2228
        Director: P W Mason MD, PhD
===============================================================================
 

Report Released Date/Time: Mar 26, 2024@06:41
Provider: CHEN,KAY JIE
  Specimen: PLASMA.           NIC 0320 47
    Specimen Collection Date: Mar 20, 2024@08:26
      Test name                Result    units      Ref.   range   Site Code
VITAMIN K1                     1180     pg/mL      130 - 1500       [73367]
Comment:  
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics Nichols Institute Chantilly, VA. It has
        not been cleared or approved by the U.S. Food and Drug
        Administration. This assay has been validated pursuant
        to the CLIA regulations and is used for clinical
        purposes.
         
        TEST PERFORMED AT:
        Quest Diagnostics/Nichols Chantilly
        14225 Newbrook Dr
        Chantilly, VA 20151-2228
        Director: P W Mason MD, PhD
===============================================================================
 

Report Released Date/Time: Mar 20, 2024@13:44
Provider: CHEN,KAY JIE
  Specimen: SERUM.            CH 0320 257
    Specimen Collection Date: Mar 20, 2024@08:26
      Test name                Result    units      Ref.   range   Site Code
AST                              42 H   IU/L       10 - 35          [664]
ALT                              26     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             65     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.6     mg/dL      0.4 - 1.2        [664]
DIRECT BILIRUBIN               <0.1     mg/dL      0 - 0.2          [664]
ALBUMIN LEVEL                   3.7     g/dL       3.2 - 4.6        [664]
PROTEIN, TOTAL                  6.7     g/dL       6.0 - 8.0        [664]
FERRITIN                        249     ng/mL      30 - 400         [664]
TRANSFERRIN                     215     mg/dL      200 - 400        [664]
IRON LEVEL                       66     ug/dl      36 - 160         [664]
IRON SATURATION (%)              22     %          20 - 50          [664]
TIBC                            301     ug/dL      228 - 428        [664]
VITAMIN B12 LEVEL               493     pg/mL      210 - 1020       [664]
FOLATE LEVEL                    4.2     ng/mL      4.0 - 20         [664]
Comment: FOL:
        Taking unusually large doses of biotin can interfere with this
        immunoassay test results. Biotin has a very short half-life and it
        is cleared within 12 hours. Patients should not take Biotin
        supplements the day of a specimen collection.  
===============================================================================
 

Report Released Date/Time: Apr 02, 2024@07:25
Provider: CHEN,KAY JIE
  Specimen: SERUM.            NIC 0320 45
    Specimen Collection Date: Mar 20, 2024@08:26
      Test name                Result    units      Ref.   range   Site Code
RETINOL                          63     mcg/dL     38 - 98          [73367]
Alpha-Tocopherol (Vit E)       15.3     mg/L                        [73367]
gToco                           1.0     mg/L       Ref: <=4.4       [73367]
Comment: **Clin Chem Vol. 34.No.8. pp1625-1628. 1998
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA 91355-5386
        Director: T McDonald MD
        Vit E, Alpha Tocopherol
              Reference Range
              5.7-19.9 mg/L
         
              Levels of alpha-tocopherol <5 mg/L are
              consistent with Vitamin E deficiency in
              adults.
        Vitamin supplementation within 24 hours prior to
        blood draw may affect the accuracy of results.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA 91355-5386
        Director: T McDonald MD
===============================================================================
 

Report Released Date/Time: Mar 05, 2024@14:52
Provider: MAO,JIMMY JINGLI
  Specimen: SERUM.            IM 0304 302
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            26.0 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Mar 11, 2024@09:10
Provider: MAO,JIMMY JINGLI
  Specimen: PLASMA.           NIC 0304 611
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
PTHrP CLINICAL                   10 L   pg/mL      11 - 20          [73367]
Comment:  
        This is a C-terminal PTH-RP assay. PTH-RP is useful in the
        differential diagnosis of hypercalcemia and levels may be
        elevated in patients with tumor-associated hypercalcemia.
        Elevated results may also be observed in patients with renal
        disease.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by FDA. This assay has
        been validated pursuant to the CLIA regulations and is used
        for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Mar 08, 2024@13:02
Provider: MAO,JIMMY JINGLI
  Specimen: SERUM.            TS 0304 12
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
KAPPA (SERUM)                  44.8 H   mg/L       3.3 - 19.4       [678]
LAMBDA (SERUM)                 33.3 H   mg/L       5.7 - 26.3       [678]
KAPPA/LAMBDA RATIO             1.35                0.26 - 1.65      [678]
Comment: Ratio reference range in severe renal failure: 0.37 - 3.10
        Testing performed at:
             Southern Arizona VA Health Care System
             3601 South Sixth Avenue
             Tucson, AZ 85723
===============================================================================
 

Report Released Date/Time: Mar 08, 2024@08:33
Provider: MAO,JIMMY JINGLI
  Specimen: SERUM.            NIC 0304 606
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
Vitamin D3, 1,25 (OH)2           75     pg/mL                       [73367]
Vitamin D2, 1,25 (OH)2           <8     pg/mL                       [73367]
1,25-DI                          75 H   pg/mL      18 - 72          [73367]
Comment:  
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        Vitamin D3, 1,25(OH)2 indicates both endogenous
        production and supplementation. Vitamin D2, 1,25(OH)2
        is an indicator of exogenous sources, such as diet or
        supplementation. Interpretation and therapy are based
        on measurement of Vitamin D, 1,25 (OH)2, Total.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        For additional information, please refer to
        http://education.QuestDiagnostics.com/faq/FAQ199
        (This link is being provided for informational/
        educational purposes only.)
        TEST PERFORMED AT:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA 91355-5386
        Director: T McDonald MD
===============================================================================
 

Report Released Date/Time: Mar 05, 2024@14:52
Provider: MAO,JIMMY JINGLI
  Specimen: SERUM.            IM 0304 291
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
Total Protein (SPEP)            6.7     g/dL       6.0 - 8.0        [664]
Albumin (SPEP)                 3.78     g/dL       3.40 - 4.80      [664]
ALPHA-1 GLOBULIN               0.37     g/dL       0.20 - 0.40      [664]
ALPHA-2 GLOBULIN               0.67     g/dL       0.50 - 0.90      [664]
BETA-1 GLOBULIN                0.36     g/dL       0.30 - 0.60      [664]
BETA-2 GLOBULIN                0.40     g/dL       0.20 - 0.50      [664]
GAMMA GLOBULIN                 1.13     g/dL       0.70 - 1.70      [664]
SERUM IEP                  Normal serum protein electrophoresis 
                                                   Ref: Normal serum protein electrophoresis
                                                                    [664]
IGG TOTAL                      1305     mg/dL      740 - 1400       [664]
IGA TOTAL                       243     mg/dL      83 - 407         [664]
IGM TOTAL                        38     mg/dL      34 - 213         [664]
Comment: Results Reviewed by: David Herold, MD, PhD.
===============================================================================
 

Report Released Date/Time: Mar 04, 2024@20:56
Provider: MAO,JIMMY JINGLI
  Specimen: SERUM.            CH 0304 775
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.7     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  105     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             22 L   mMol/L     24 - 31          [664]
BUN                              15     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.59 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       49 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            87     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            10.8 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.5     mg/dL      2.5 - 4.7        [664]
AGAP                             10     mMol/L     6 - 15           [664]
ALBUMIN LEVEL                   3.7     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Mar 07, 2024@13:43
Provider: MAO,JIMMY JINGLI
  Specimen: URINE.            IM 0304 290
    Specimen Collection Date: Mar 04, 2024@11:45
      Test name                Result    units      Ref.   range   Site Code
Urine IEP                  Polyclonal Immunoglobulins 
                                                   Ref: No protein detected
                                                                    [664]
Comment: Full complement of proteins observed. 
        Results Reviewed by: David Herold, MD, PhD. 
===============================================================================
 

Report Released Date/Time: Jan 24, 2024@13:36
Provider: ABDELMALEK,JOSEPH
  Specimen: NARES.            IDS 24 1497
    Specimen Collection Date: Jan 22, 2024@18:29
      Test name                Result    units      Ref.   range   Site Code
MRSA SURVL NARES AGAR      Negative                Ref: Negative    [664]
===============================================================================
 

Report Released Date/Time: Jan 22, 2024@12:03
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0122 169
    Specimen Collection Date: Jan 22, 2024@11:58
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 114 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735374, Serial Number:UU14523334
===============================================================================
 

Report Released Date/Time: Jan 22, 2024@06:43
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0122 23
    Specimen Collection Date: Jan 22, 2024@06:42
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 104 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:483991, Serial Number:UU14457800
===============================================================================
 

Report Released Date/Time: Jan 22, 2024@08:19
Provider: PATERNOSTRO,KEVIN A
  Specimen: BLOOD.            HE 0122 38
    Specimen Collection Date: Jan 22, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                             5.1     K/uL       4.8 - 10.8       [664]
RBC                            3.20 L   M/uL       4.7 - 5.6        [664]
HGB                             9.1 L   g/dL       12.4 - 17.4      [664]
HCT                            26.8 L   %          38 - 52          [664]
MCV                            83.8     fL         80 - 100         [664]
MCH                            28.4     pg         26 - 31          [664]
MCHC                           34.0     g/dL       32 - 36          [664]
RDW-SD                         40.6     fL         35.1 - 46.3      [664]
RDW-CV                         13.2     %          13 - 15          [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                           0.0     K/uL       0 - 0.012        [664]
PLT                             314     K/uL       140 - 400        [664]
MPV                             9.8     fL         9.1 - 12.5       [664]
SEGS %                         65.0     %          45.0 - 65.0      [664]
LYMPHS %                       18.2 L   %          20.0 - 40.0      [664]
MONOS %                        14.0 H   %          2.0 - 10.0       [664]
EOSINO %                        1.6     %          0.0 - 3.0        [664]
BASO %                          1.0     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.0 - 0.8        [664]
SEG #                           3.3     K/uL       2.24 - 6.46      [664]
LYMPH #                         0.9     K/uL       0.73 - 3.44      [664]
MONO #                          0.7     K/uL       0.25 - 0.97      [664]
EOSINO #                        0.1     K/uL       0.01 - 0.57      [664]
BASO #                          0.1     K/uL       0.01 - 0.10      [664]
IG #                            0.0     K/uL       0.0 - 0.07       [664]
===============================================================================
 

Report Released Date/Time: Jan 22, 2024@09:21
Provider: PATERNOSTRO,KEVIN A
  Specimen: SERUM.            CH 0122 42
    Specimen Collection Date: Jan 22, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.5     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  110 H   mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             22 L   mMol/L     24 - 31          [664]
BUN                               4 L   mg/dL      8 - 23           [664]
CREATININE LEVEL               1.45 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       54 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            93     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.9     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.4 L   mg/dL      2.5 - 4.7        [664]
AGAP                              5 L   mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.6     mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.0 L   g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@19:31
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0121 168
    Specimen Collection Date: Jan 21, 2024@19:30
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 120 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:483991, Serial Number:UU14386470
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@16:49
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0121 122
    Specimen Collection Date: Jan 21, 2024@16:45
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 174 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735433, Serial Number:UU14457800
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@11:58
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0121 90
    Specimen Collection Date: Jan 21, 2024@11:54
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 174 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:735433, Serial Number:UU14386470
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@06:56
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0121 42
    Specimen Collection Date: Jan 21, 2024@06:49
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 123 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:739443, Serial Number:UU14386470
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@11:55
Provider: FANG,CHRISTINA D
  Specimen: SERUM.            CH 0121 120
    Specimen Collection Date: Jan 21, 2024@06:35
      Test name                Result    units      Ref.   range   Site Code
FERRITIN                        390     ng/mL      30 - 400         [664]
===============================================================================
 

Report Released Date/Time: Jan 26, 2024@07:07
Provider: FANG,CHRISTINA D
  Specimen: SERUM.            NIC 0121 183
    Specimen Collection Date: Jan 21, 2024@06:35
      Test name                Result    units      Ref.   range   Site Code
Vitamin D3, 1,25 (OH)2          101     pg/mL                       [73367]
Vitamin D2, 1,25 (OH)2           <8     pg/mL                       [73367]
1,25-DI                         101 H   pg/mL      18 - 72          [73367]
Comment:  
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        Vitamin D3, 1,25(OH)2 indicates both endogenous
        production and supplementation. Vitamin D2, 1,25(OH)2
        is an indicator of exogenous sources, such as diet or
        supplementation. Interpretation and therapy are based
        on measurement of Vitamin D, 1,25 (OH)2, Total.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest
        Diagnostics. It has not been cleared or approved by the
        FDA. This assay has been validated pursuant to the CLIA
        regulations and is used for clinical purposes.
         
        For additional information, please refer to
        http://education.QuestDiagnostics.com/faq/FAQ199
        (This link is being provided for informational/
        educational purposes only.)
        TEST PERFORMED AT:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA 91355-5386
        Director: T McDonald MD
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@11:17
Provider: FANG,CHRISTINA D
  Specimen: SERUM.            CH 0121 114
    Specimen Collection Date: Jan 21, 2024@06:35
      Test name                Result    units      Ref.   range   Site Code
TRANSFERRIN                     174 L   mg/dL      200 - 400        [664]
IRON LEVEL                       45     ug/dl      36 - 160         [664]
IRON SATURATION (%)              19 L   %          20 - 50          [664]
TIBC                            244     ug/dL      228 - 428        [664]
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@07:51
Provider: PEI,ALLISON
  Specimen: BLOOD.            HE 0121 23
    Specimen Collection Date: Jan 21, 2024
      Test name                Result    units      Ref.   range   Site Code
WBC                             5.3     K/uL       4.8 - 10.8       [664]
RBC                            3.28 L   M/uL       4.7 - 5.6        [664]
HGB                             9.4 L   g/dL       12.4 - 17.4      [664]
HCT                            27.2 L   %          38 - 52          [664]
MCV                            82.9     fL         80 - 100         [664]
MCH                            28.7     pg         26 - 31          [664]
MCHC                           34.6     g/dL       32 - 36          [664]
RDW-SD                         39.3     fL         35.1 - 46.3      [664]
RDW-CV                         12.9 L   %          13 - 15          [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                           0.0     K/uL       0 - 0.012        [664]
PLT                             332     K/uL       140 - 400        [664]
MPV                             9.9     fL         9.1 - 12.5       [664]
SEGS %                         72.0 H   %          45.0 - 65.0      [664]
LYMPHS %                       13.7 L   %          20.0 - 40.0      [664]
MONOS %                        12.4 H   %          2.0 - 10.0       [664]
EOSINO %                        1.1     %          0.0 - 3.0        [664]
BASO %                          0.6     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.0 - 0.8        [664]
SEG #                           3.8     K/uL       2.24 - 6.46      [664]
LYMPH #                         0.7 L   K/uL       0.73 - 3.44      [664]
MONO #                          0.7     K/uL       0.25 - 0.97      [664]
EOSINO #                        0.1     K/uL       0.01 - 0.57      [664]
BASO #                          0.0 L   K/uL       0.01 - 0.10      [664]
IG #                            0.0     K/uL       0.0 - 0.07       [664]
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@08:40
Provider: PEI,ALLISON
  Specimen: SERUM.            CH 0121 25
    Specimen Collection Date: Jan 21, 2024
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.5     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  108 H   mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                               7 L   mg/dL      8 - 23           [664]
CREATININE LEVEL               1.61 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       48 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           116 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            11.6 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                2.7     mg/dL      2.5 - 4.7        [664]
AGAP                              6     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.3 L   mg/dL      1.6 - 2.5        [664]
ALBUMIN LEVEL                   3.1 L   g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Jan 21, 2024@00:30
Provider: PEI,ALLISON
  Specimen: BLOOD.            AT 0121 4
    Specimen Collection Date: Jan 20, 2024@23:56
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 130 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:217920, Serial Number:UU14457800
===============================================================================
 

Report Released Date/Time: Jan 24, 2024@13:31
Provider: PEI,ALLISON
  Specimen: URINE.            IM 0120 24
    Specimen Collection Date: Jan 20, 2024@21:15
      Test name                Result    units      Ref.   range   Site Code
Urine IEP                  Trace Albumin 
                                                   Ref: No protein detected
                                                                    [664]
Comment: Trace Albumin detected. 
        Results Reviewed by: David Herold, MD, PhD. 
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@22:00
Provider: PEI,ALLISON
  Specimen: PLASMA.           CH 0120 309
    Specimen Collection Date: Jan 20, 2024@21:00
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                           9 L   pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Jan 24, 2024@17:03
Provider: PEI,ALLISON
  Specimen: SERUM.            TS 0120 1
    Specimen Collection Date: Jan 20, 2024@21:00
      Test name                Result    units      Ref.   range   Site Code
KAPPA (SERUM)                  38.8 H   mg/L       3.3 - 19.4       [678]
LAMBDA (SERUM)                 26.7 H   mg/L       5.7 - 26.3       [678]
KAPPA/LAMBDA RATIO             1.45                0.26 - 1.65      [678]
Comment: Ratio reference range in severe renal failure: 0.37 - 3.10
        Testing performed at:
             Southern Arizona VA Health Care System
             3601 South Sixth Avenue
             Tucson, AZ 85723
===============================================================================
 

Report Released Date/Time: Jan 23, 2024@11:18
Provider: PEI,ALLISON
  Specimen: SERUM.            IM 0120 23
    Specimen Collection Date: Jan 20, 2024@21:00
      Test name                Result    units      Ref.   range   Site Code
Total Protein (SPEP)            6.6     g/dL       6.0 - 8.0        [664]
Albumin (SPEP)                 3.52     g/dL       3.40 - 4.80      [664]
ALPHA-1 GLOBULIN               0.35     g/dL       0.20 - 0.40      [664]
ALPHA-2 GLOBULIN               0.84     g/dL       0.50 - 0.90      [664]
BETA-1 GLOBULIN                0.36     g/dL       0.30 - 0.60      [664]
BETA-2 GLOBULIN                0.44     g/dL       0.20 - 0.50      [664]
GAMMA GLOBULIN                 1.10     g/dL       0.70 - 1.70      [664]
SERUM IEP                  Normal serum protein electrophoresis 
                                                   Ref: Normal serum protein electrophoresis
                                                                    [664]
IGG TOTAL                      1272     mg/dL      740 - 1400       [664]
IGA TOTAL                       262     mg/dL      83 - 407         [664]
IGM TOTAL                        34     mg/dL      34 - 213         [664]
Comment: Results Reviewed by: David Herold, MD, PhD.
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@22:30
Provider: PEI,ALLISON
  Specimen: SERUM.            CH 0120 308
    Specimen Collection Date: Jan 20, 2024@21:00
      Test name                Result    units      Ref.   range   Site Code
PROTEIN, TOTAL                  6.1     g/dL       6.0 - 8.0        [664]
THYROID STIMULATING HORMONE    1.67     mIU/L      0.49 - 4.67      [664]
===============================================================================
 

Report Released Date/Time: Jan 22, 2024@16:47
Provider: PEI,ALLISON
  Specimen: SERUM.            IM 0120 22
    Specimen Collection Date: Jan 20, 2024@21:00
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            25.2 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Feb 26, 2024@06:42
Provider: PEI,ALLISON
  Specimen: PLASMA.           NIC 0120 176
    Specimen Collection Date: Jan 20, 2024@21:00
      Test name                Result    units      Ref.   range   Site Code
PTHrP CLINICAL                   11     pg/mL      11 - 20          [73367]
Comment:  
        This is a C-terminal PTH-RP assay. PTH-RP is useful in the
        differential diagnosis of hypercalcemia and levels may be
        elevated in patients with tumor-associated hypercalcemia.
        Elevated results may also be observed in patients with renal
        disease.
         
        This test was developed and its analytical performance
        characteristics have been determined by Quest Diagnostics.
        It has not been cleared or approved by FDA. This assay has
        been validated pursuant to the CLIA regulations and is used
        for clinical purposes.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@20:48
Provider: STENDARDI,WILLIAM FROST
  Specimen: PLASMA.           CH 0120 299
    Specimen Collection Date: Jan 20, 2024@20:00
      Test name                Result    units      Ref.   range   Site Code
zTROPONIN-I HS                 33.7     ng/L       Ref: <=39.0      [664]
Comment: ~#3 of 3. To be drawn 60min after 2nd Troponin-I. 
        #3 of 3. To be drawn 60min after 2nd Troponin-I.
        Refer to clinical algorithm for decision support.
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@20:06
Provider: STENDARDI,WILLIAM FROST
  Specimen: PLASMA.           CH 0120 290
    Specimen Collection Date: Jan 20, 2024@18:35
      Test name                Result    units      Ref.   range   Site Code
zTROPONIN-I HS                 33.3     ng/L       Ref: <=39.0      [664]
Comment: ~#2 or 3. Draw 60 min after 1st Troponin-I. 
        #2 or 3. Draw 60 min after 1st Troponin-I.
        Refer to clinical algorithm for decision support.
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@19:15
Provider: STENDARDI,WILLIAM FROST
  Specimen: NARES.            IDS 24 1374
    Specimen Collection Date: Jan 20, 2024@17:59
      Test name                Result    units      Ref.   range   Site Code
MRSA SURVL NARES DNA       Negative                Ref: Negative    [664]
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@18:42
Provider: STENDARDI,WILLIAM FROST
  Specimen: NASOPHARYNX.      SOMI 0120 24
    Specimen Collection Date: Jan 20, 2024@17:58
      Test name                Result    units      Ref.   range   Site Code
INFLUENZA A SCREEN         Negative                Ref: Negative    [664]
INFLUENZA B SCREEN         Negative                Ref: Negative    [664]
      Eval: Influenza A and B testing performed by molecular (PCR) testing.
COVID-19 RNA               Not Detected 
                                                   Ref: Not Detected
                                                                    [664]
Respiratory Syncytial VirusNegative                Ref: Negative    [664]
Comment: ~Symptomatic (Admission ONLY)
        Negative results do not exclude 2019-nCoV infection and should not
        be used as the sole basis for treatment or other patient management
        decisions. If diagnosis will affect management then it may be
        necessary to collect multiple specimens to detect the virus.  
        Results were obtained using the Cepheid Infinity Xpert
        SARS-CoV-2/Flu/RSV Assay, testing completed at VA San Diego HCS
        (664).  
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@18:12
Provider: STENDARDI,WILLIAM FROST
  Specimen: PLASMA.           CO 0120 36
    Specimen Collection Date: Jan 20, 2024@17:45
      Test name                Result    units      Ref.   range   Site Code
PT                             12.5     secs       11.8 - 14.0      [664]
PTT                            28.0     secs       25.7 - 35.0      [664]
      Eval: PRIOR TO 2/13/2018 Recommended Heparin Therapeutic Range: 59.7 - 95.2 SEC
PT RATIO                        1.0                                 [664]
INR                             1.0                0.9 - 1.2        [664]
      Eval: Target ranges for the INR are:  Coumadin therapy for DVT: 2.0-3.0;  Atrial
      Eval: Fibrillation: 2.0-3.0;  Prosthetic valve: 2.5-3.5.
Comment: Recommended PTT Heparin Therapeutic Range: 63.7 - 111.6 seconds.
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@18:39
Provider: STENDARDI,WILLIAM FROST
  Specimen: SERUM.            CH 0120 274
    Specimen Collection Date: Jan 20, 2024@17:45
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    136     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.2 L   mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  100     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                               9     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.79 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       42 L              Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            74     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            13.1 H*  mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.2     mg/dL      2.5 - 4.7        [664]
AGAP                             12     mMol/L     6 - 15           [664]
MAGNESIUM LEVEL                 1.2 L   mg/dL      1.6 - 2.5        [664]
AST                              47 H   IU/L       10 - 35          [664]
ALT                              25     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             72     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.9     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
        CA Critical results called to and read back by DR RIVEST 
        @1837, 1/20/24-NAE 
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@18:09
Provider: STENDARDI,WILLIAM FROST
  Specimen: BLOOD.            HE 0120 154
    Specimen Collection Date: Jan 20, 2024@17:45
      Test name                Result    units      Ref.   range   Site Code
WBC                             7.6     K/uL       4.8 - 10.8       [664]
RBC                            3.91 L   M/uL       4.7 - 5.6        [664]
HGB                            11.1 L   g/dL       12.4 - 17.4      [664]
HCT                            33.0 L   %          38 - 52          [664]
MCV                            84.4     fL         80 - 100         [664]
MCH                            28.4     pg         26 - 31          [664]
MCHC                           33.6     g/dL       32 - 36          [664]
RDW-SD                         40.4     fL         35.1 - 46.3      [664]
RDW-CV                         13.2     %          13 - 15          [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                           0.0     K/uL       0 - 0.012        [664]
PLT                             355     K/uL       140 - 400        [664]
MPV                             9.4     fL         9.1 - 12.5       [664]
SEGS %                         68.4 H   %          45.0 - 65.0      [664]
LYMPHS %                       17.4 L   %          20.0 - 40.0      [664]
MONOS %                        11.5 H   %          2.0 - 10.0       [664]
EOSINO %                        1.7     %          0.0 - 3.0        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.3     %          0.0 - 0.8        [664]
SEG #                           5.2     K/uL       2.24 - 6.46      [664]
LYMPH #                         1.3     K/uL       0.73 - 3.44      [664]
MONO #                          0.9     K/uL       0.25 - 0.97      [664]
EOSINO #                        0.1     K/uL       0.01 - 0.57      [664]
BASO #                          0.1     K/uL       0.01 - 0.10      [664]
IG #                            0.0     K/uL       0.0 - 0.07       [664]
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@18:37
Provider: STENDARDI,WILLIAM FROST
  Specimen: PLASMA.           CH 0120 273
    Specimen Collection Date: Jan 20, 2024@17:45
      Test name                Result    units      Ref.   range   Site Code
zTROPONIN-I HS                 35.1     ng/L       Ref: <=39.0      [664]
Comment: Refer to clinical algorithm for decision support.
===============================================================================
 

Report Released Date/Time: Jan 20, 2024@18:36
Provider: STENDARDI,WILLIAM FROST
  Specimen: PLASMA.           CH 0120 272
    Specimen Collection Date: Jan 20, 2024@17:45
      Test name                Result    units      Ref.   range   Site Code
BNP (PRE 12/16/2025)          <35.0     pg/mL      2 - 100          [664]
===============================================================================
 

Report Released Date/Time: Jan 17, 2024@08:54
Provider: WEI,JENNIE H
  Specimen: BLOOD.            AT 0117 64
    Specimen Collection Date: Jan 17, 2024@08:53
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  91     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:410579, Serial Number:UU14386715
===============================================================================
 

Report Released Date/Time: Dec 15, 2023@08:57
Provider: FIX,SARA ELIZABETH
  Specimen: FECES.            MO 23 172
    Specimen Collection Date: Dec 14, 2023@15:20
      Test name                Result    units      Ref.   range   Site Code
Campylobacter              not detected 
                                                   Ref: not detected
                                                                    [664]
Salmonella                 not detected 
                                                   Ref: not detected
                                                                    [664]
Vibrio                     not detected 
                                                   Ref: not detected
                                                                    [664]
Vibrio cholera             not detected 
                                                   Ref: not detected
                                                                    [664]
Yersinia enterocolitica    not detected 
                                                   Ref: not detected
                                                                    [664]
EPEC                       not detected 
                                                   Ref: not detected
                                                                    [664]
Cryptosporidium            not detected 
                                                   Ref: not detected
                                                                    [664]
Cyclospora cayetanensis    not detected 
                                                   Ref: not detected
                                                                    [664]
Entamoeba histolytica      not detected 
                                                   Ref: not detected
                                                                    [664]
Giardia lamblia            not detected 
                                                   Ref: not detected
                                                                    [664]
Adenovirus F40/41          not detected 
                                                   Ref: not detected
                                                                    [664]
Astrovirus                 not detected 
                                                   Ref: not detected
                                                                    [664]
Norovirus GI/GII           not detected 
                                                   Ref: not detected
                                                                    [664]
Rotavirus A                not detected 
                                                   Ref: not detected
                                                                    [664]
Sapovirus                  not detected 
                                                   Ref: not detected
                                                                    [664]
Plesiomonas shigelloides   not detected 
                                                   Ref: not detected
                                                                    [664]
EAEC                       not detected 
                                                   Ref: not detected
                                                                    [664]
ETEC                       not detected 
                                                   Ref: not detected
                                                                    [664]
Shiga-like tox Ecoli       not detected 
                                                   Ref: not detected
                                                                    [664]
Shig/Entero Ecoli          not detected 
                                                   Ref: not detected
                                                                    [664]
Comment: ~For Test: GI PCR PANEL
        ~GI PCR PANEL REPLACED STOOL C&S 
        Test performed using a comprehensive multiplex PCR assay (FilmArray
        system). For Detected bacterial targets, when susceptibilities are
        indicated, cultures will be performed for further identification,
        typing and/or susceptibilities. Clinical correlation is needed, as
        low levels of nucleic acids may be present in the raw materials
        used to produce transport media and may lead to false positive
        results.  
===============================================================================
 

Report Released Date/Time: Dec 26, 2023@06:27
Provider: FIX,SARA ELIZABETH
  Specimen: FECES.            NIC 1214 510
    Specimen Collection Date: Dec 14, 2023@10:45
      Test name                Result    units      Ref.   range   Site Code
PANCREATIC ELASTASE-1, STOOL      46 L  mcg/g                       [73367]
Comment: Pancreatic Elastase-1
         
        Adult and Pediatric Reference Ranges for
          Pancreatic Elastase-1:
         
                     Normal:      >200 mcg/g
        Moderate Pancreatic
              Insufficiency:   100-200 mcg/g
          Severe Pancreatic
              Insufficiency:      <100 mcg/g
         
        Elastase-1 (E-1) assay results are expressed
        in mcg/g, which represent mcg E1/g feces.
         
        It is not necessary to interrupt enzyme
        substitution therapy.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Dec 22, 2023@07:12
Provider: FIX,SARA ELIZABETH
  Specimen: FECES.            NIC 1214 509
    Specimen Collection Date: Dec 14, 2023@10:45
      Test name                Result    units      Ref.   range   Site Code
CALPROTECTIN, STOOL             324 H   mcg/g                       [73367]
Comment: Calprotectin, Stool
                                              Reference Range:
                                              <50     Normal
                                              50-120  Borderline
                                              >120    Elevated
         
        Calprotectin in Crohn's disease and ulcerative colitis can
        be five to several thousand times above the reference
        population (50 mcg/g or less). Levels are usually 50 mcg/g
        or less in healthy patients and with irritable bowel
        syndrome. Repeat testing in 4-6 weeks is suggested for
        borderline values.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Dec 17, 2023@20:12
Provider: FIX,SARA ELIZABETH
  Specimen: FECES.            IDS 23 24384
    Specimen Collection Date: Dec 14, 2023@10:45
      Test name                Result    units      Ref.   range   Site Code
Giardia Ag                 Negative                Ref: Negative    [664]
Cryptosporidium Ag         Negative                Ref: Negative    [664]
===============================================================================
 

Report Released Date/Time: Dec 19, 2023@06:52
Provider: FIX,SARA ELIZABETH
  Specimen: FECES.            NIC 1214 508
    Specimen Collection Date: Dec 14, 2023@10:45
      Test name                Result    units      Ref.   range   Site Code
FECAL FAT, QUALITATIVE       NORMAL                Ref: NORMAL      [73367]
Comment: *ELECTROLYTES, FECES Not Performed: Dec 15, 2023@12:51 by 120201
        *NP Reason: Specimen too formed. Teams msg to PA Fix 12/15/23.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Dec 14, 2023@16:33
Provider: FIX,SARA ELIZABETH
  Specimen: FECES.            IDS 23 24383
    Specimen Collection Date: Dec 14, 2023@10:45
      Test name                Result    units      Ref.   range   Site Code
C DIFF TOX B GENE PCR      Negative                Ref: Negative    [664]
Comment: ~ARE CDI CRITERIA MET?
===============================================================================
 
                            ---- MICROBIOLOGY ----
Accession [UID]: MI 23 12622 [1223012622]   Received: Dec 14, 2023@11:48
Collection sample: STOOL               Collection date: Dec 14, 2023 10:45
Site/Specimen: FECES
Provider: FIX,SARA ELIZABETH
Comment on specimen: 
*CULTURE & SUSCEPTIBILITY Not Performed: Dec 14, 2023@15:23 by 22353
                                                                               
                                                                               
 Test(s) ordered: CULTURE & SUSCEPTIBILITY...... canceled: Dec 14, 2023 15:23

===============================================================================
 

Report Released Date/Time: Dec 05, 2023@19:13
Provider: WEI,JENNIE H
  Specimen: PLASMA.           CH 1205 976
    Specimen Collection Date: Dec 05, 2023@13:50
      Test name                Result    units      Ref.   range   Site Code
PTH-INT                          <6 L   pg/mL      15 - 75          [664]
===============================================================================
 

Report Released Date/Time: Dec 05, 2023@17:58
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 1205 975
    Specimen Collection Date: Dec 05, 2023@13:50
      Test name                Result    units      Ref.   range   Site Code
CALCIUM LEVEL TOTAL            12.4 H   mg/dL      8.5 - 10.4       [664]
===============================================================================
 

Report Released Date/Time: Dec 01, 2023@18:01
Provider: FIX,SARA ELIZABETH
  Specimen: BLOOD.            HE 1201 446
    Specimen Collection Date: Dec 01, 2023@14:41
      Test name                Result    units      Ref.   range   Site Code
WBC                             5.6     K/uL       4.8 - 10.8       [664]
RBC                            3.94 L   M/uL       4.7 - 5.6        [664]
HGB                            11.3 L   g/dL       12.4 - 17.4      [664]
HCT                            33.1 L   %          38 - 52          [664]
MCV                            84.0     fL         80 - 100         [664]
MCH                            28.7     pg         26 - 31          [664]
MCHC                           34.1     g/dL       32 - 36          [664]
RDW-SD                         40.9     fL         35.1 - 46.3      [664]
RDW-CV                         13.2     %          13 - 15          [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                           0.0     K/uL       0 - 0.012        [664]
PLT                             345     K/uL       140 - 400        [664]
MPV                            10.3     fL         9.1 - 12.5       [664]
SEGS %                         59.0     %          45.0 - 65.0      [664]
LYMPHS %                       23.7     %          20.0 - 40.0      [664]
MONOS %                        13.9 H   %          2.0 - 10.0       [664]
EOSINO %                        2.3     %          0.0 - 3.0        [664]
BASO %                          0.9     %          0.0 - 1.0        [664]
IG %                            0.2     %          0.0 - 0.8        [664]
SEG #                           3.3     K/uL       2.24 - 6.46      [664]
LYMPH #                         1.3     K/uL       0.73 - 3.44      [664]
MONO #                          0.8     K/uL       0.25 - 0.97      [664]
EOSINO #                        0.1     K/uL       0.01 - 0.57      [664]
BASO #                          0.1     K/uL       0.01 - 0.10      [664]
IG #                            0.0     K/uL       0.0 - 0.07       [664]
===============================================================================
 

Report Released Date/Time: Dec 13, 2023@07:11
Provider: FIX,SARA ELIZABETH
  Specimen: SERUM.            NIC 1201 443
    Specimen Collection Date: Dec 01, 2023@14:41
      Test name                Result    units      Ref.   range   Site Code
tTG Ab, IgA                    <1.0     U/mL                        [73367]
IGA TOTAL                       228     mg/dL      70 - 320         [73367]
Comment: No serological evidence for celiac disease is present. tTg
        may normalize in individuals with celiac disease who
        maintain a gluten free diet. If high suspicion of celiac
        disease, consider HLA DQ2 and DQ8 testing to rule out celiac
        disease.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
         
         
        Units Value      Interpretation
        -----------      --------------
        <15.0            Antibody not detected
        > or = 15.0      Antibody detected
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
         
         
        Units Value      Interpretation
        -----------      --------------
        <15.0            Antibody not detected
        > or = 15.0      Antibody detected
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
         
         
        Units Value      Interpretation
        -----------      --------------
        <15.0            Antibody not detected
        > or = 15.0      Antibody detected
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Dec 01, 2023@21:05
Provider: FIX,SARA ELIZABETH
  Specimen: SERUM.            CH 1201 932
    Specimen Collection Date: Dec 01, 2023@14:41
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    140     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.7     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  106     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             23 L   mMol/L     24 - 31          [664]
BUN                              10     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.13     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       73                Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           124 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            12.6 H   mg/dL      8.5 - 10.4       [664]
AGAP                             11     mMol/L     6 - 15           [664]
AST                              48 H   IU/L       10 - 35          [664]
ALT                              29     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             54     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.5     mg/dL      0.4 - 1.2        [664]
DIRECT BILIRUBIN               <0.1     mg/dL      0 - 0.2          [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
PROTEIN, TOTAL                  6.6     g/dL       6.0 - 8.0        [664]
AMYLASE LEVEL                   115 H   IU/L       28 - 85          [664]
LIPASE LEVEL                     33     U/L        13 - 42          [664]
CRP UltraSens                  0.96 H   mg/dL      Ref: <=0.8       [664]
THYROID STIMULATING HORMONE    1.56     mIU/L      0.49 - 4.67      [664]
FERRITIN                        204     ng/mL      30 - 400         [664]
TRANSFERRIN                     231     mg/dL      200 - 400        [664]
IRON LEVEL                       66     ug/dl      36 - 160         [664]
IRON SATURATION (%)              20     %          20 - 50          [664]
TIBC                            323     ug/dL      228 - 428        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Nov 29, 2023@16:59
Provider: WEI,JENNIE H
  Specimen: URINE.            CH 1129 529
    Specimen Collection Date: Nov 29, 2023@10:43
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE      123.80     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.01     mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       0.9     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Nov 29, 2023@16:43
Provider: WEI,JENNIE H
  Specimen: SERUM.            IM 1129 150
    Specimen Collection Date: Nov 29, 2023@10:43
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            28.0 L   ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Dec 14, 2023@07:04
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 1129 289
    Specimen Collection Date: Nov 29, 2023@10:43
      Test name                Result    units      Ref.   range   Site Code
tTG Ab, IgA                    <1.0     U/mL                        [73367]
IGA TOTAL                       226     mg/dL      70 - 320         [73367]
Comment: No serological evidence for celiac disease is present. tTg
        may normalize in individuals with celiac disease who
        maintain a gluten free diet. If high suspicion of celiac
        disease, consider HLA DQ2 and DQ8 testing to rule out celiac
        disease.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
         
         
        Units Value      Interpretation
        -----------      --------------
        <15.0            Antibody not detected
        > or = 15.0      Antibody detected
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
         
         
        Units Value      Interpretation
        -----------      --------------
        <15.0            Antibody not detected
        > or = 15.0      Antibody detected
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
        Test not performed. Reflex testing not required since
        established criteria was not met.
         
         
        Units Value      Interpretation
        -----------      --------------
        <15.0            Antibody not detected
        > or = 15.0      Antibody detected
        TEST PERFORMED AT:
        Quest Diagnostics Nichols Institute
        33608 Ortega Highway
        San Juan Capistrano, CA 92675-2042
        Director: I Maramica MD, PhD, MBA
===============================================================================
 

Report Released Date/Time: Nov 29, 2023@16:59
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 1129 526
    Specimen Collection Date: Nov 29, 2023@10:43
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           1.75     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.9     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  103     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             25     mMol/L     24 - 31          [664]
BUN                              11     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.20     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       68                Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            74     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL            12.1 H   mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.7     mg/dL      2.5 - 4.7        [664]
AGAP                             10     mMol/L     6 - 15           [664]
AST                              49 H   IU/L       10 - 35          [664]
ALT                              33     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             54     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.6     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   4.0     g/dL       3.2 - 4.6        [664]
AMYLASE LEVEL                   112 H   IU/L       28 - 85          [664]
LIPASE LEVEL                     32     U/L        13 - 42          [664]
CHOLESTEROL (PRE 12/16/2025)     137 L  mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              87     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  29     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)      106     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
CRP UltraSens                  1.13 H   mg/dL      Ref: <=0.8       [664]
THYROID STIMULATING HORMONE    1.48     mIU/L      0.49 - 4.67      [664]
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
        eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Nov 30, 2023@10:14
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 1129 127
    Specimen Collection Date: Nov 29, 2023@10:43
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  5.7     %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        http://www.ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Nov 29, 2023@16:37
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 1129 327
    Specimen Collection Date: Nov 29, 2023@10:43
      Test name                Result    units      Ref.   range   Site Code
WBC                             5.2     K/uL       4.8 - 10.8       [664]
RBC                            3.99 L   M/uL       4.7 - 5.6        [664]
HGB                            11.6 L   g/dL       12.4 - 17.4      [664]
HCT                            33.9 L   %          38 - 52          [664]
MCV                            85.0     fL         80 - 100         [664]
MCH                            29.1     pg         26 - 31          [664]
MCHC                           34.2     g/dL       32 - 36          [664]
RDW-SD                         40.8     fL         35.1 - 46.3      [664]
RDW-CV                         13.2     %          13 - 15          [664]
PLT                             347     K/uL       140 - 400        [664]
MPV                            10.2     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Nov 14, 2023@10:49
Provider: WEI,JENNIE H
  Specimen: BLOOD.            AT 1114 98
    Specimen Collection Date: Nov 14, 2023@10:44
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 117 H   mg/dL      70  -  99        [664]
Comment: For Glu: Operator:764445, Serial Number:UU14386715
===============================================================================
 

Report Released Date/Time: Mar 27, 2023@12:26
Provider: JOSEPH,RONALD D
  Specimen: BLOOD.            HE 0327 354
    Specimen Collection Date: Mar 27, 2023@10:55
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.2     K/uL       4.8 - 10.8       [664]
RBC                            4.55 L   M/uL       4.7 - 5.6        [664]
HGB                            13.2     g/dL       12.4 - 17.4      [664]
HCT                            39.1     %          38 - 52          [664]
MCV                            85.9     fL         80 - 100         [664]
MCH                            29.0     pg         26 - 31          [664]
MCHC                           33.8     g/dL       32 - 36          [664]
RDW-SD                         39.2     fL         35.1 - 46.3      [664]
RDW-CV                         12.5 L   %          13 - 15          [664]
PLT                             307     K/uL       140 - 400        [664]
MPV                            10.8     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Mar 27, 2023@13:15
Provider: JOSEPH,RONALD D
  Specimen: SERUM.            CH 0327 655
    Specimen Collection Date: Mar 27, 2023@10:55
      Test name                Result    units      Ref.   range   Site Code
SODIUM LEVEL                    134 L   mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.9     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  105     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                              19     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.14     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       73                Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            86     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.5     mg/dL      8.5 - 10.4       [664]
AGAP                              5 L   mMol/L     6 - 15           [664]
AST                              24     IU/L       10 - 35          [664]
ALT                              23     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             51     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.8     mg/dL      0.4 - 1.2        [664]
DIRECT BILIRUBIN                0.1     mg/dL      0 - 0.2          [664]
ALBUMIN LEVEL                   4.2     g/dL       3.2 - 4.6        [664]
PROTEIN, TOTAL                  7.0     g/dL       6.0 - 8.0        [664]
FERRITIN                         63     ng/mL      30 - 400         [664]
TRANSFERRIN                     260     mg/dL      200 - 400        [664]
IRON LEVEL                      108     ug/dl      36 - 160         [664]
IRON SATURATION (%)              30     %          20 - 50          [664]
TIBC                            364     ug/dL      228 - 428        [664]
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Mar 28, 2023@14:06
Provider: RYBA,BRYAN EDWARD
  Specimen: BLOOD.            CRCH 0327 199
    Specimen Collection Date: Mar 27, 2023@10:54
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  7.7 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        http://www.ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Mar 27, 2023@12:49
Provider: JOSEPH,RONALD D
  Specimen: SERUM.            CH 0327 649
    Specimen Collection Date: Mar 27, 2023@10:54
      Test name                Result    units      Ref.   range   Site Code
BUN                              18     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.22     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       67                Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
Comment: eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Sep 20, 2022@06:37
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0916 7
    Specimen Collection Date: Sep 16, 2022@07:10
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  7.5 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
         
        Target A1C values should be individualized. Values obtained from
        A1C measurements can vary.  For typical A1C assays, a reported
        value of 7.0 could actually be between 6.72 and 7.28 if measured by
        a reference method.  A reported value of 9.0 could actually be
        between 8.73 and 9.27. Providers should contact the Laboratory
        (x7758) for performance characteristics of this assay. Ref:
        http://www.ngsp.org/CAPdata.asp 
===============================================================================
 

Report Released Date/Time: Sep 16, 2022@10:11
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0916 73
    Specimen Collection Date: Sep 16, 2022@07:10
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.0     K/uL       4.8 - 10.8       [664]
RBC                            4.18 L   M/uL       4.7 - 5.6        [664]
HGB                            11.9 L   g/dL       12.4 - 17.4      [664]
HCT                            35.9 L   %          38 - 52          [664]
MCV                            85.9     fL         80 - 100         [664]
MCH                            28.5     pg         26 - 31          [664]
MCHC                           33.1     g/dL       32 - 36          [664]
RDW-SD                         38.5     fL         35.1 - 46.3      [664]
RDW-CV                         12.4 L   %          13 - 15          [664]
NRBC                            0.0     /100 WBC   0.0 - 0.2        [664]
NRBC#                           0.0     K/uL       0 - 0.012        [664]
PLT                             301     K/uL       140 - 400        [664]
MPV                            10.1     fL         9.1 - 12.5       [664]
SEGS %                         44.4 L   %          45.0 - 65.0      [664]
LYMPHS %                       37.3     %          20.0 - 40.0      [664]
MONOS %                        10.3 H   %          2.0 - 10.0       [664]
EOSINO %                        7.0 H   %          0.0 - 3.0        [664]
BASO %                          0.7     %          0.0 - 1.0        [664]
IG %                            0.3     %          0.0 - 0.8        [664]
SEG #                           2.7     K/uL       2.24 - 6.46      [664]
LYMPH #                         2.3     K/uL       0.73 - 3.44      [664]
MONO #                          0.6     K/uL       0.25 - 0.97      [664]
EOSINO #                        0.4     K/uL       0.01 - 0.57      [664]
BASO #                          0.0 L   K/uL       0.01 - 0.10      [664]
IG #                            0.0     K/uL       0.0 - 0.07       [664]
===============================================================================
 

Report Released Date/Time: Sep 16, 2022@10:25
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0916 4
    Specimen Collection Date: Sep 16, 2022@07:10
      Test name                Result    units      Ref.   range   Site Code
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.011                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: <NEGATIVE   [664]
NITRITE, URINE             NEGATIVE                Ref: <NEGATIVE   [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: <NEGATIVE   [664]
UR PROTEIN                 NEGATIVE                Ref: <NEGATIVE   [664]
URINE GLUCOSE              NEGATIVE                Ref: <NEGATIVE   [664]
URINE KETONES              NEGATIVE                Ref: <NEGATIVE   [664]
UROBILINOGEN,URINE              2.0     mg/dL      Ref: <=2.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: <NEGATIVE   [664]
Comment: Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
        Review abnormal urobilinogen results to determine if they are
        consistent with the patient's other clinical findings and result
        parameters.  
===============================================================================
 

Report Released Date/Time: Sep 16, 2022@10:47
Provider: WEI,JENNIE H
  Specimen: URINE.            CH 0916 94
    Specimen Collection Date: Sep 16, 2022@07:10
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       78.28     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.01     mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       0.6     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Sep 16, 2022@11:19
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0916 93
    Specimen Collection Date: Sep 16, 2022@07:10
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           2.33     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.7     mMol/L     3.5 - 5.0        [664]
BUN                              14     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.26     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       65                Ref: >=60        [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            80     mg/dL      70 - 99          [664]
AST                              27     IU/L       10 - 35          [664]
ALT                              25     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             51     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.8     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     165    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                             101     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  53     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       54     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
THYROID STIMULATING HORMONE    1.81     mIU/L      0.49 - 4.67      [664]
TRANSFERRIN                     251     mg/dL      200 - 400        [664]
IRON LEVEL                       68     ug/dl      36 - 160         [664]
IRON SATURATION (%)              19 L   %          20 - 50          [664]
TIBC                            351     ug/dL      228 - 428        [664]
VITAMIN B12 LEVEL               786     pg/mL      210 - 1020       [664]
FOLATE LEVEL                   14.2     ng/mL      4.0 - 20         [664]
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
        FOL:
        Taking unusually large doses of biotin can interfere with this
        immunoassay test results. Biotin has a very short half-life and it
        is cleared within 12 hours. Patients should not take Biotin
        supplements the day of a specimen collection.  
        eGFR CKD-EPI
        eGFR calculated using the 2021 CKD-EPI-creatinine equation; units
        of measure are mL/min/1.73m~2.  
        eGFR can only be interpreted if creatinine is in  steady state and
        is not valid in patients with acute kidney injury and in patients
        on dialysis.  
         
        CKD is diagnosed based on abnormalities of kidney structure or
        function, present for >3 months, with implications for health and
        disease. CKD is classified and stage based on cause, eGFR and
        albuminuria, quantified as urine albumin to creatinine ratio.  
            eGFR staging of CKD
                 Stage G1              eGFR >90 mL/min/1.73m~2
                 Stage G2              eGFR 60-89 mL/min/1.73m~2
                 Stage G3a             eGFR 45-59 mL/min/1.73m~2
                 Stage G3b             eGFR 30-44 mL/min/1.73m~2
                 Stage G4              eGFR 15-29 mL/min/1.73m~2
                 Stage G5              eGFR <15 mL/min/1.73m~2
===============================================================================
 

Report Released Date/Time: Mar 31, 2022@14:49
Provider: WEI,JENNIE H
  Specimen: BLOOD.            AT 0331 268
    Specimen Collection Date: Mar 31, 2022@14:36
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                  80     mg/dL      70  -  99        [664]
Comment: For Glu: Operator:291370, Serial Number:UU14386715
===============================================================================
 

Report Released Date/Time: Nov 30, 2021@08:59
Provider: CABALLERO,SAMIRA JEZELL
  Specimen: BLOOD.            AT 1130 80
    Specimen Collection Date: Nov 30, 2021@08:56
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 114 H   mg/dL      70  -  99        [664]
Comment: Glucose:  
        Glucose: Test performed by: 489031 Meter #: UU14386715
===============================================================================
 

Report Released Date/Time: Nov 30, 2021@09:21
Provider: CABALLERO,SAMIRA JEZELL
  Specimen: NARES.            AT 1130 83
    Specimen Collection Date: Nov 30, 2021@08:40
      Test name                Result    units      Ref.   range   Site Code
COVID-19 Antigen (AT Binax)Not Detected 
                                                   Ref: Not Detected
                                                                    [664]
Comment: Nasal swab specimen collected and test was performed using the
        point of care 
                            Abbott Binax Now.
        COVID-19 Screening Antigen Testing
          Quality Control: Valid
          Patient result: Negative
          Test Kit Lot Number: Lot #145512 Exp: 01/14/2022
         
         
        Testing done at VA San Diego
          During your visit you were tested for COVID-19. The COVID-19 test
        was 
          negative.
            Recommendations:
              - Minimize contact with others until 24 hours
                after symptoms resolve.
         
         
              Steps to prevent the spread of COVID-19:
                - Stay at home except to get medical care or other essential
                  business.
                - Monitor your symptoms. Please call or return to the
                  Emergency Department if you experience worsening shortness
                  of breath, fever, or are feeling worse in any way.
                - Get rest and stay hydrated.
                - Call ahead before visiting your doctor.
                - For medical emergencies, call 911 and notify the dispatch
                  personnel that you have or may have COVID-19.
                - Wear a facemask if you are sick around others. Cover your
                  cough and sneezes.
                - Clean your hands often.
                - Practice social distancing. Keep 6 feet apart as much
                  as possible.
                - Avoid sharing household items.
                - Disinfect high touch surfaces daily, ideally with a
        product 
                  that kills cold and flu viruses.
         
        Testing performed on Abbott BinaxNOW (664) under FDA Emergency Use
        Authorization (EUA).  
        A positive result indicates the presence SARS-CoV-2 nucleocapsid
        protein, and likely represents SARS-CoV-2 infection in patients
        with symptoms.  
        A negative result does not completely rule out the possibility of
        COVID-19.  
        Symptomatic patients with negative BinaxNOW results should have
        SARS-CoV-2 RT-PCR testing to rule out infection.  
        NOTE: These results must be accompanied with following Fact Sheets
        for: 
        Health Care Providers: https://www.fda.gov/media/142435/download
        Patients: https://www.fda.gov/media/142436/download
         
===============================================================================
 

Report Released Date/Time: Nov 02, 2021@06:33
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 1029 53
    Specimen Collection Date: Oct 29, 2021@08:15
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  6.7 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
        Target A1C values should be individualized. Better understanding of
        A1C test result accuracy is essential if clinicians are to
        interpret results for Veterans and discuss treatment options
        through the process of Shared Decision Making. Patients should
        contact their providers for interpretation of results. Providers
        should contact the Laboratory (x7758) for performance
        characteristics of this assay.  
===============================================================================
 

Report Released Date/Time: Oct 29, 2021@14:30
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 1029 238
    Specimen Collection Date: Oct 29, 2021@08:15
      Test name                Result    units      Ref.   range   Site Code
FERRITIN                         10 L   ng/mL      30 - 400         [664]
TRANSFERRIN                     292     mg/dL      200 - 400        [664]
IRON LEVEL                       34 L   ug/dl      36 - 160         [664]
IRON SATURATION (%)               8 L   %          20 - 50          [664]
TIBC                            409     ug/dL      228 - 428        [664]
VITAMIN B12 LEVEL             >1200 H   pg/mL      210 - 1020       [664]
FOLATE LEVEL                   11.4     ng/mL      4.0 - 20         [664]
Comment: FOL:
        Taking unusually large doses of biotin can interfere with this
        immunoassay test results. Biotin has a very short half-life and it
        is cleared within 12 hours. Patients should not take Biotin
        supplements the day of a specimen collection.  
===============================================================================
 

Report Released Date/Time: Sep 01, 2021@14:21
Provider: WEI,JENNIE H
  Specimen: BLOOD.            AT 0901 226
    Specimen Collection Date: Sep 01, 2021@14:20
      Test name                Result    units      Ref.   range   Site Code
AT- GLUCOSE POC                 120 H   mg/dL      70  -  99        [664]
Comment: Glucose:  
        Glucose: Test performed by: 500269 Meter #: UU14386715
===============================================================================
 

Report Released Date/Time: Jun 11, 2021@13:45
Provider: WEI,JENNIE H
  Specimen: URINE.            CH 0611 412
    Specimen Collection Date: Jun 11, 2021@09:29
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE      128.42     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.01     mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       0.8     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Jun 11, 2021@12:57
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0611 61
    Specimen Collection Date: Jun 11, 2021@09:29
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.013                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: <NEGATIVE   [664]
NITRITE, URINE             NEGATIVE                Ref: <NEGATIVE   [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: <NEGATIVE   [664]
UR PROTEIN                 NEGATIVE                Ref: <NEGATIVE   [664]
URINE GLUCOSE              NEGATIVE                Ref: <NEGATIVE   [664]
URINE KETONES              NEGATIVE                Ref: <NEGATIVE   [664]
UROBILINOGEN,URINE              2.0     mg/dL      Ref: <=2.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: <NEGATIVE   [664]
Comment: ~Clean Catch Urine
        Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
        Review abnormal urobilinogen results to determine if they are
        consistent with the patient's other clinical findings and result
        parameters.  
===============================================================================
 

Report Released Date/Time: Jun 11, 2021@13:59
Provider: WEI,JENNIE H
  Specimen: SERUM.            IM 0611 89
    Specimen Collection Date: Jun 11, 2021@09:29
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            43.5     ng/mL      30.0 - 100.0     [664]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
===============================================================================
 

Report Released Date/Time: Jun 11, 2021@13:45
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0611 410
    Specimen Collection Date: Jun 11, 2021@09:29
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           3.39     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.0     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                  103     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             26     mMol/L     24 - 31          [664]
BUN                              14     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.29     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       70 L              94 - 140         [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           149 H   mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.5     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.8     mg/dL      2.5 - 4.7        [664]
AGAP                              8     mMol/L     6 - 15           [664]
AST                              28     IU/L       10 - 35          [664]
ALT                              27     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             63     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 1.0     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.7     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     173    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                             114     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  46     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       65     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
THYROID STIMULATING HORMONE    0.90     mIU/L      0.49 - 4.67      [664]
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
===============================================================================
 

Report Released Date/Time: Jun 14, 2021@13:12
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0611 113
    Specimen Collection Date: Jun 11, 2021@09:29
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  9.1 H   %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
        Target A1C values should be individualized. Better understanding of
        A1C test result accuracy is essential if clinicians are to
        interpret results for Veterans and discuss treatment options
        through the process of Shared Decision Making. Patients should
        contact their providers for interpretation of results. Providers
        should contact the Laboratory (x7758) for performance
        characteristics of this assay.  
===============================================================================
 

Report Released Date/Time: Jun 11, 2021@18:25
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0611 185
    Specimen Collection Date: Jun 11, 2021@09:29
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.2     K/uL       4.8 - 10.8       [664]
RBC                            4.43 L   M/uL       4.7 - 5.6        [664]
HGB                            10.9 L   g/dL       12.4 - 17.4      [664]
HCT                            34.2 L   %          38 - 52          [664]
MCV                            77.2 L   fL         80 - 100         [664]
MCH                            24.6 L   pg         26 - 31          [664]
MCHC                           31.9 L   g/dL       32 - 36          [664]
RDW-SD                         43.1     fL         35.1 - 46.3      [664]
RDW-CV                         15.6 H   %          13 - 15          [664]
PLT                             360     K/uL       140 - 400        [664]
MPV                            10.6     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Dec 03, 2020@15:05
Provider: WEI,JENNIE H
  Specimen: NASOPHARYNX.      SOMI 1202 86
    Specimen Collection Date: Dec 02, 2020@08:20
      Test name                Result    units      Ref.   range   Site Code
COVID-19 RNA               Not Detected 
                                                   Ref: Not Detected
                                                                    [600]
Comment: ~Routine Screening
        The specimen is negative for SARS-CoV-2, the coronavirus associated
        with COVID-19. A negative result does not rule out the possibility
        of COVID-19.
        Test performed on Roche Cobas 6800 (600), Cobas SARS-CoV-2
        qualitative assay.
        This test has been authorized by the FDA under an  Emergency Use
        Authorization (EUA) for use by  authorized laboratories.
        Please review the Fact Sheets for health care providers and
        patients:
        https://www.fda.gov/media/136047/download
        https://www.fda.gov/media/136048/download
===============================================================================
 

Report Released Date/Time: Apr 11, 2019@15:25
Provider: WEI,JENNIE H
  Specimen: URINE 24H.        CH 0411 516
    Specimen Collection Date: Apr 11, 2019@11:12
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE      130.08                                 [664]
MICROALBUMIN/CREAT RATIO       0.01                                 [664]
MICROALBUMIN LEVEL, URINE       1.6                                 [664]
===============================================================================
 

Report Released Date/Time: Apr 15, 2019@07:12
Provider: WEI,JENNIE H
  Specimen: SERUM.            LB 0411 168
    Specimen Collection Date: Apr 11, 2019@11:12
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            38.3     ng/mL      30 - 140         [600]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: Vitamin D status
        < 20ng/ml         deficiency
        20-29 ng/ml       insufficiency
        30-100 ng/ml      sufficiency
        >140-150 ng/ml    intoxication
         
        Reference: J Clin Endocrinol Metab 96:1911-1930, 2011
===============================================================================
 

Report Released Date/Time: Apr 11, 2019@15:22
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0411 515
    Specimen Collection Date: Apr 11, 2019@11:12
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           2.17     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    137     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.1     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                   99     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             23 L   mMol/L     24 - 31          [664]
BUN                              13     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.38 H   mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       64 L              94 - 140         [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            73     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.9     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.9     mg/dL      2.5 - 4.7        [664]
AGAP                             15     mMol/L     6 - 15           [664]
AST                              36 H   IU/L       10 - 35          [664]
ALT                              27     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             57     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 1.0     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   4.0     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     133 L  mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              81     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  36     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       79     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
Comment: ~If Triglycerides >400, please measure direct LDL.
        If Triglycerides >400, please measure direct LDL.
===============================================================================
 

Report Released Date/Time: Apr 11, 2019@15:58
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0411 109
    Specimen Collection Date: Apr 11, 2019@11:12
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.012                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: NEGATIVE    [664]
NITRITE, URINE             NEGATIVE                Ref: NEGATIVE    [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: NEGATIVE    [664]
UR PROTEIN                 NEGATIVE                Ref: NEGATIVE    [664]
URINE GLUCOSE              NEGATIVE                Ref: NEGATIVE    [664]
URINE KETONES              NEGATIVE                Ref: NEGATIVE    [664]
UROBILINOGEN,URINE              4.0 H              Ref: <=2.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: NEGATIVE    [664]
Comment: ~Clean Catch Urine
        Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
        Review abnormal urobilinogen results to determine if they are
        consistent with the patient's other clinical findings and result
        parameters.  
===============================================================================
 

Report Released Date/Time: Apr 12, 2019@14:57
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0411 145
    Specimen Collection Date: Apr 11, 2019@11:12
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  5.8     %          4.8 - 6.4        [664]
Comment: Reference Range:
        Normal: 4.8-5.6%
        Pre-Diabetes: 5.7-6.4%
        Diabetes: >=6.5%
        Target A1C values should be individualized. Better understanding of
        A1C test result accuracy is essential if clinicians are to
        interpret results for Veterans and discuss treatment options
        through the process of Shared Decision Making. Patients should
        contact their providers for interpretation of results. Providers
        should contact the Laboratory (x7758) for performance
        characteristics of this assay.  
===============================================================================
 

Report Released Date/Time: Apr 11, 2019@16:23
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0411 275
    Specimen Collection Date: Apr 11, 2019@11:12
      Test name                Result    units      Ref.   range   Site Code
WBC                             5.6     K/uL       4.8 - 10.8       [664]
RBC                            4.23 L   M/uL       4.7 - 5.6        [664]
HGB                            11.7 L   g/dL       12.4 - 17.4      [664]
HCT                            36.3 L   %          38 - 52          [664]
MCV                            85.8     fL         80 - 100         [664]
MCH                            27.7     pg         26 - 31          [664]
MCHC                           32.2     g/dL       32 - 36          [664]
RDW-SD                         42.6     fL         35.1 - 46.3      [664]
RDW-CV                         13.7     %          13 - 15          [664]
PLT                             315     K/uL       140 - 400        [664]
MPV                            10.1     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Apr 09, 2018@15:54
Provider: WEI,JENNIE H
  Specimen: URINE.            CH 0409 634
    Specimen Collection Date: Apr 09, 2018@11:07
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       88.90     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.01     mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       1.1     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Apr 11, 2018@08:34
Provider: WEI,JENNIE H
  Specimen: SERUM.            LB 0409 337
    Specimen Collection Date: Apr 09, 2018@11:07
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            41.1     ng/mL      30 - 140         [600]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: Vitamin D status
        < 20ng/ml         deficiency
        20-29 ng/ml       insufficiency
        30-100 ng/ml      sufficiency
        >140-150 ng/ml    intoxication
         
        Reference: J Clin Endocrinol Metab 96:1911-1930, 2011
===============================================================================
 

Report Released Date/Time: Apr 09, 2018@18:54
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0409 633
    Specimen Collection Date: Apr 09, 2018@11:07
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           0.71     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    135     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 4.1     mMol/L     3.5 - 5.0        [664]
CHLORIDE LEVEL                   99     mMol/L     95 - 106         [664]
CARBON DIOXIDE LEVEL             24     mMol/L     24 - 31          [664]
BUN                              14     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.12     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       82 L              94 - 140         [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            74     mg/dL      70 - 99          [664]
CALCIUM LEVEL TOTAL             9.5     mg/dL      8.5 - 10.4       [664]
PHOSPHORUS LEVEL                3.2     mg/dL      2.5 - 4.7        [664]
AGAP                             12     mMol/L     6 - 15           [664]
AST                              50 H   IU/L       10 - 35          [664]
ALT                              47 H   IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             54     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.7     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   3.9     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     131 L  mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              79     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  37     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       75     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
THYROID STIMULATING HORMONE    1.15     mIU/L      0.49 - 4.67      [664]
Comment: ~If Triglycerides >400, please measure direct LDL.
===============================================================================
 

Report Released Date/Time: Apr 09, 2018@16:36
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0409 101
    Specimen Collection Date: Apr 09, 2018@11:07
      Test name                Result    units      Ref.   range   Site Code
Culture required?                NO                                 [664]
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.012                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: NEG         [664]
NITRITE, URINE             NEGATIVE                Ref: NEG         [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: NEG         [664]
UR PROTEIN                 NEGATIVE                Ref: NEG         [664]
URINE GLUCOSE              NEGATIVE                Ref: NEG         [664]
URINE KETONES              NEGATIVE                Ref: NEG         [664]
UROBILINOGEN,URINE             <2.0                Ref: <=1.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: NEG         [664]
Comment: ~Clean Catch Urine
        Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
===============================================================================
 

Report Released Date/Time: Apr 10, 2018@08:32
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0409 224
    Specimen Collection Date: Apr 09, 2018@11:07
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  6.8 H   %          4.8 - 6.2        [664]
Comment: Target A1C values should be individualized. Better understanding of
        A1C test result accuracy is essential if clinicians are to
        interpret results for Veterans and discuss treatment options
        through the process of Shared Decision Making. Patients should
        contact their providers for interpretation of results. Providers
        should contact the Laboratory (x7758) for performance
        characteristics of this assay.  
        Hemoglobin variant identified as S. 
===============================================================================
 

Report Released Date/Time: Apr 09, 2018@17:23
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0409 359
    Specimen Collection Date: Apr 09, 2018@11:07
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.4     K/uL       4.8 - 10.8       [664]
RBC                            4.21 L   M/uL       4.7 - 5.6        [664]
HGB                            11.0 L   g/dL       12.4 - 17.4      [664]
HCT                            34.8 L   %          38 - 52          [664]
MCV                            82.7     fL         80 - 100         [664]
MCH                            26.1     pg         26 - 31          [664]
MCHC                           31.6 L   g/dL       32 - 36          [664]
RDW-SD                         42.8     fL         35.1 - 46.3      [664]
RDW-CV                         14.3     %          13 - 15          [664]
PLT                             296     K/uL       140 - 400        [664]
MPV                            10.9     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Jul 07, 2017@15:50
Provider: WEI,JENNIE H
  Specimen: URINE.            CH 0707 369
    Specimen Collection Date: Jul 07, 2017@09:49
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE      100.07     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.00     mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       0.4     mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: Jul 07, 2017@13:28
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0707 79
    Specimen Collection Date: Jul 07, 2017@09:49
      Test name                Result    units      Ref.   range   Site Code
Culture required?               YES                                 [664]
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.013                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE     TRACE                Ref: NEG         [664]
NITRITE, URINE             NEGATIVE                Ref: NEG         [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: NEG         [664]
UR PROTEIN                 NEGATIVE                Ref: NEG         [664]
URINE GLUCOSE              NEGATIVE                Ref: NEG         [664]
URINE KETONES              NEGATIVE                Ref: NEG         [664]
UROBILINOGEN,URINE             <2.0                Ref: <=1.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: NEG         [664]
HYALINE CASTS                   0-4     /LPF       0 - 4            [664]
EPITH CELLS                     FEW                                 [664]
MUCUS                           FEW                                 [664]
WBC/HPF                         0-2     /HPF       0 - 2            [664]
RBC/HPF                         0-2     /HPF       0 - 2            [664]
Comment: ~Clean Catch Urine
        Reducing agents such as Ascorbic Acid, Uric Acid, Glutathione and
        Gentisic acid may cause interference with urine blood test
        resulting in a false negative.  
        Specimen sent to Microbiology for culture. 
===============================================================================
 

Report Released Date/Time: Jul 11, 2017@09:01
Provider: WEI,JENNIE H
  Specimen: SERUM.            LB 0707 165
    Specimen Collection Date: Jul 07, 2017@09:49
      Test name                Result    units      Ref.   range   Site Code
VIT D Total (25-OH)            43.1     ng/mL      30 - 140         [600]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: Vitamin D status
        < 20ng/ml         deficiency
        20-29 ng/ml       insufficiency
        30-100 ng/ml      sufficiency
        >140-150 ng/ml    intoxication
         
        Reference: J Clin Endocrinol Metab 96:1911-1930, 2011
===============================================================================
 

Report Released Date/Time: Jul 07, 2017@16:27
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0707 368
    Specimen Collection Date: Jul 07, 2017@09:49
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           0.65     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    138     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.8     mMol/L     3.5 - 5.0        [664]
BUN                              15     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.21     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       75 L              94 - 140         [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            83     mg/dL      70 - 99          [664]
AST                              35     IU/L       10 - 35          [664]
ALT                              32     IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             46     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.6     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   4.1     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     146    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              87     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  43     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       81     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
THYROID STIMULATING HORMONE    1.57     mIU/mL     0.49 - 4.67      [664]
Comment: ~^
        ~^
        ~If Triglycerides >400, please measure direct LDL.
===============================================================================
 

Report Released Date/Time: Jul 08, 2017@10:36
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0707 123
    Specimen Collection Date: Jul 07, 2017@09:49
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  6.6 H   %          4.8 - 6.2        [664]
Comment: Target A1C values should be individualized. Better understanding of
        A1C test result accuracy is essential if clinicians are to
        interpret results for Veterans and discuss treatment options
        through the process of Shared Decision Making. Patients should
        contact their providers for interpretation of results. Providers
        should contact the Laboratory (x7758) for performance
        characteristics of this assay.  
        Hemoglobin variant identified 
===============================================================================
 

Report Released Date/Time: Jul 07, 2017@12:59
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0707 196
    Specimen Collection Date: Jul 07, 2017@09:49
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.3     K/uL       4.8 - 10.8       [664]
RBC                            3.89 L   M/uL       4.7 - 5.6        [664]
HGB                            11.1 L   g/dL       12.4 - 17.4      [664]
HCT                            33.2 L   %          38 - 52          [664]
MCV                            85.3     fL         80 - 100         [664]
MCH                            28.5     pg         26 - 31          [664]
MCHC                           33.4     g/dL       32 - 36          [664]
RDW-SD                         42.3     fL         35.1 - 46.3      [664]
RDW-CV                         13.6     %          13 - 15          [664]
PLT                             335     K/uL       140 - 400        [664]
MPV                            10.5     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Jun 15, 2016@14:38
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0615 132
    Specimen Collection Date: Jun 15, 2016@09:35
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  6.7 H   %          4.8 - 6.2        [664]
Comment: Target A1C values should be individualized. Better understanding of
        A1C test result accuracy is essential if clinicians are to
        interpret results for Veterans and discuss treatment options
        through the process of Shared Decision Making. Patients should
        contact their providers for interpretation of results. Providers
        should contact the Laboratory (x7758) for performance
        characteristics of this assay.  
        Hemoglobin variant identified 
===============================================================================
 

Report Released Date/Time: Jun 15, 2016@13:32
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0615 209
    Specimen Collection Date: Jun 15, 2016@09:35
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.5     K/uL       4.8 - 10.8       [664]
RBC                            4.22 L   M/uL       4.7 - 5.6        [664]
HGB                            11.6 L   g/dL       12.4 - 17.4      [664]
HCT                            35.8 L   %          38 - 52          [664]
MCV                            84.8     fL         80 - 100         [664]
MCH                            27.5     pg         26 - 31          [664]
MCHC                           32.4     g/dL       32 - 36          [664]
RDW-SD                         43.2     fL         35.1 - 46.3      [664]
RDW-CV                         14.0     %          13 - 15          [664]
PLT                             312     K/uL       140 - 400        [664]
MPV                            10.7     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: Jun 17, 2016@07:01
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 0615 332
    Specimen Collection Date: Jun 15, 2016@09:35
      Test name                Result    units      Ref.   range   Site Code
VIT D2 (25-OH)                   <4     ng/mL      Ref: Not established
                                                                    [72024]
VIT D3 (25-OH)                   12     ng/mL      Ref: Not established
                                                                    [72024]
VIT D Total (25-OH)              12 L   ng/mL      30 - 100         [72024]
      Eval: Vitamin D status:
      Eval: <20.0 ng/mL          deficiency
      Eval: 20.0 - 29.0 ng/mL    insufficiency
      Eval: 30.0 - 100.0 ng/mL   sufficiency
      Eval: >150.0 ng/mL         intoxication
      Eval:  
      Eval:  
      Eval: Prior to 10/5/2020:
      Eval: Vitamin D status:
      Eval: <20 ng/ml         deficiency 
      Eval: 20-29 ng/ml       insufficiency
      Eval: 30-100 ng/ml      sufficiency
      Eval: >140-150 ng/ml    intoxication
      Eval: Reference: J Clin Endocrinol Metab 96:1911-1930, 2011 
      Eval:  
      Eval: Prior to 9/29/2016:
      Eval: Methodology: LC/MS/MS on ABI 4000 triple quadrupole mass 
      Eval: spectrometry.
      Eval: Optimal concentrations for 25-OH Vit D have not been determined.  
      Eval: General consensus is that the total 25-OH Vit D3 (sum of 25-OH 
      Eval: Vit D3 and 25-OH Vit D2) should be greater than 35 ng/mL. Patients
      Eval: with total Vitamin D less than 35 ng/mL should be considered for
      Eval: supplementation. Please direct questions to 858-552-8585 x7758.
Comment: Vitamin D, 25-OH, Total
         
         25-OHD3 indicates both endogenous production and
        supplementation. 25-OHD2 is an indicator of exogenous
        sources, such as diet or supplementation. Therapy is based
        on measurement of Total 25-OHD, with levels <20 ng/mL
        indicative of Vitamin D deficiency, while levels between 20
        ng/mL and 30 ng/mL suggest insufficiency. Optimal levels are
        > or = 30 ng/mL.
        Test Performed at:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA  91355-5386     B Kashlan MD, FCAP
===============================================================================
 

Report Released Date/Time: Jun 15, 2016@13:44
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0615 336
    Specimen Collection Date: Jun 15, 2016@09:35
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           0.89     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    135     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.8     mMol/L     3.5 - 5.0        [664]
BUN                              11     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.13     mg/dL      0.6 - 1.3        [664]
EGFR CKD EPI(PRE 12/18/25)       82 L              94 - 140         [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM            76     mg/dL      70 - 99          [664]
AST                              47 H   IU/L       10 - 35          [664]
ALT                              49 H   IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             48     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.8     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   4.1     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     155    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              98     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  45     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       62     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
Comment: ~^
        ~^
        ~If Triglycerides >400, please measure direct LDL.
===============================================================================
 

Report Released Date/Time: Jun 15, 2016@14:00
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0615 62
    Specimen Collection Date: Jun 15, 2016@09:35
      Test name                Result    units      Ref.   range   Site Code
Culture required?               YES                                 [664]
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                   STRAW                                 [664]
SPECIFIC GRAVITY              1.008                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE     TRACE                Ref: NEG         [664]
NITRITE, URINE             NEGATIVE                Ref: NEG         [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: NEG         [664]
UR PROTEIN                 NEGATIVE                Ref: NEG         [664]
URINE GLUCOSE              NEGATIVE                Ref: NEG         [664]
URINE KETONES              NEGATIVE                Ref: NEG         [664]
UROBILINOGEN,URINE             <2.0                Ref: <=1.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: NEG         [664]
EPITH CELLS                     FEW                                 [664]
WBC/HPF                         0-2     /HPF       0 - 2            [664]
RBC/HPF                         0-2     /HPF       0 - 2            [664]
Comment: ~Clean Catch Urine
        Specimen sent to Microbiology for culture. 
===============================================================================
 

Report Released Date/Time: May 31, 2015@16:28
Provider: WEI,JENNIE H
  Specimen: FECES.            STOOL 15 3071
    Specimen Collection Date: May 29, 2015@07:13
      Test name                Result    units      Ref.   range   Site Code
OCCULT BLOOD (FIT) #1 OF 1 Negative                Ref: Negative    [664]
      Eval: FIT is an immunological test developed to detect human globin - the 
      Eval: protein part of hemoglobin - it is specific for bleeding from the distal 
      Eval: gut. Negative results for the immunological test do not assure absence of 
      Eval: GI bleeding or pathology. Gastrointestinal lesions may bleed 
      Eval: intermittently and blood in feces is not distributed evenly. This 
      Eval: screening is not intended to replace other diagnostic procedures such as 
      Eval: colonoscopy or sigmoidoscopy in combination with double contrast barium 
      Eval: x-rays, and is not intended for patients with upper GI bleeds. Bowel 
      Eval: lesions, including some polyps and colorectal cancers may not bleed at all
      Eval: or bleed intermittently.
===============================================================================
 

Report Released Date/Time: May 18, 2015@13:14
Provider: WEI,JENNIE H
  Specimen: SERUM.            NIC 0514 241
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
TESTOSTERONE TOTAL              412     ng/dL      250 - 1100       [72024]
Comment:  
        Test Performed at:
        Quest Diagnostics Valencia
        Nichols Institute, 27027 Tourney Road
        Valencia, CA  91355-5386     B Kashlan MD, FCAP
===============================================================================
 

Report Released Date/Time: May 14, 2015@13:41
Provider: WEI,JENNIE H
  Specimen: URINE.            CH 0514 298
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
(IMMUNOLOGY) CREATININE       87.70     mg/dL                       [664]
MICROALBUMIN/CREAT RATIO       0.11 H   mg/mg      0 - 0.03         [664]
MICROALBUMIN LEVEL, URINE       9.5 H   mg/dL      0.0 - 2.0        [664]
===============================================================================
 

Report Released Date/Time: May 14, 2015@12:53
Provider: WEI,JENNIE H
  Specimen: URINE.            UA 0514 60
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
APPEARANCE                    CLEAR                                 [664]
URINE COLOR                  YELLOW                                 [664]
SPECIFIC GRAVITY              1.012                1.003 - 1.035    [664]
LEUKOCYTE ESTERASE, URINE  NEGATIVE                Ref: NEG         [664]
NITRITE, URINE             NEGATIVE                Ref: NEG         [664]
URINE PH                        5.0                4.5 - 8.5        [664]
URINE BLOOD                NEGATIVE                Ref: NEG         [664]
UR PROTEIN                 NEGATIVE                Ref: NEG         [664]
URINE GLUCOSE              NEGATIVE                Ref: NEG         [664]
URINE KETONES              NEGATIVE                Ref: NEG         [664]
UROBILINOGEN,URINE              4.0 H              Ref: <=1.0       [664]
URINE BILIRUBIN            NEGATIVE                Ref: NEG         [664]
Comment: ~Clean Catch Urine
===============================================================================
 

Report Released Date/Time: May 15, 2015@12:01
Provider: WEI,JENNIE H
  Specimen: SERUM.            SPCH 0514 19
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
zAntHCV                    Negative                Ref: NEG         [664]
      Eval: All First Time REACTIVE HCV Screen Results will be
      Eval: confirmed by HCV VIRAL LOAD.
===============================================================================
 

Report Released Date/Time: May 14, 2015@13:33
Provider: WEI,JENNIE H
  Specimen: SERUM.            CH 0514 297
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
PSA (PRE 12/16/2025)           0.75     ng/mL      0.0 - 4.0        [664]
      Eval: Abnormal Lab Result Alerts are generated for
      Eval: patients who have a PSA result >0.03 and a concurrent
      Eval: ICD Diagnosis of:
      Eval: 1) MALIGN NEOPL PROSTATE
      Eval: 2) HX-PROSTATIC MALIGNANCY
      Eval: 3) DYSPLASIA OF PROSTATE
      Eval: 4) CA IN SITU PROSTATE
      Eval: 5) UNC BEHAV NEO PROSTATE
SODIUM LEVEL                    141     mMol/L     135 - 145        [664]
POTASSIUM LEVEL                 3.9     mMol/L     3.5 - 5.0        [664]
BUN                              13     mg/dL      8 - 23           [664]
CREATININE LEVEL               1.12     mg/dL      0.4 - 1.2        [664]
EGFR CKD EPI(PRE 12/18/25)       83 L              94 - 140         [664]
      Eval: As of 1/12/2022: using the 2021 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: From 3/24/2020-1/12/2022: using the 2012 CKD-EPI Creatinine Equation.
      Eval:  
      Eval: Prior To 3/24/2020: using the MDRD Equation.
GLUCOSE LEVEL, RANDOM           126 H   mg/dL      70 - 99          [664]
AST                              45 H   IU/L       10 - 35          [664]
ALT                              64 H   IU/L       10 - 40          [664]
ALKALINE PHOSPHATASE             62     IU/L       38 - 126         [664]
BILIRUBIN TOTAL                 0.7     mg/dL      0.4 - 1.2        [664]
ALBUMIN LEVEL                   4.1     g/dL       3.2 - 4.6        [664]
CHOLESTEROL (PRE 12/16/2025)     157    mg/dL      140 - 240        [664]
      Eval: Desirable Cholesterol <200
      Eval: Borderline High  200-239
      Eval: High >240  
LDL                              99     mg/dl      3 - 130          [664]
HDL CHOLESTEROL                  46     mg/dL      Ref: >36         [664]
TRIGLYCERIDE(PRE 12/16/25)       62     mg/dL      Ref: <=150       [664]
      Eval: Desirable Triglyceride is <150 mg/dL.
THYROID STIMULATING HORMONE    2.14     mIU/mL     0.49 - 4.67      [664]
Comment: ~^
        ~^
        ~If Triglycerides >400, please measure direct LDL.
===============================================================================
 

Report Released Date/Time: May 16, 2015@12:47
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0514 229
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
HEMOGLOBIN A1C                  7.8 H   %          4.8 - 6.2        [664]
Comment: Hemoglobin AS trait tentatively identified in this patient 
===============================================================================
 

Report Released Date/Time: May 14, 2015@13:17
Provider: WEI,JENNIE H
  Specimen: BLOOD.            HE 0514 163
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
WBC                             6.1     K/uL       4.8 - 10.8       [664]
RBC                            4.92     M/uL       4.7 - 5.6        [664]
HGB                            12.8     g/dL       12.4 - 17.4      [664]
HCT                            40.6     %          38 - 52          [664]
MCV                            82.5     fL         80 - 100         [664]
MCH                            26.0     pg         26 - 31          [664]
MCHC                           31.5 L   g/dL       32 - 36          [664]
RDW-SD                         43.0     fL         35.1 - 46.3      [664]
RDW-CV                         14.5     %          13 - 15          [664]
PLT                             260     K/uL       140 - 400        [664]
MPV                            11.6     fL         9.1 - 12.5       [664]
===============================================================================
 

Report Released Date/Time: May 20, 2015@07:25
Provider: WEI,JENNIE H
  Specimen: BLOOD.            CRCH 0516 7
    Specimen Collection Date: May 14, 2015@09:01
      Test name                Result    units      Ref.   range   Site Code
RBC (Hgb Dis Pan)              4.92     M/uL       4.7 - 5.6        [664]
MCV (Hgb Dis Panel)            82.5     fL         80 - 100         [664]
RDW (Hgb Dis Panel)            14.5     %          13 - 15          [664]
Hgb (Hgb Dis Panel)            12.8     g/dL       12.4 - 17.4      [664]
HCT (Hgb Dis Pan)              40.6     %          39 - 52          [664]
Hemoglobin A                   61.2 L   %          95 - 100         [664]
Hemoglobin S                   35.1 H   %          0 - 0            [664]
HEMOGLOBIN VARIANTS         PRESENT H*             Ref: None Detected
                                                                    [664]
Comment: HEMOGLOBIN S @ 35.1% CONSISTENT WITH AS TRAIT 
===============================================================================
 
Performing Lab Sites
[596]   LEXINGTON VAMC-LEESTOWN [CLIA# 18D0987409]
        1101 VETERANS DRIVE Leestown Road LEXINGTON, KY 40511-1052
[600]   VA LONG BEACH HEALTHCARE SYSTEM [CLIA# 05D0988227]
        5901 EAST 7TH ST LONG BEACH, CA 90822-5201
[664]   VA SAN DIEGO HEALTHCARE SYSTEM (664) [CLIA# 05D0988249]
        3350 La Jolla Village Drive San Diego, CA 92161-0002
[678]   SOUTHERN ARIZONA HEALTH CARE SYSTEM - TUCSON DIVISION [CLIA# 03D0987884]
        3601 SOUTH 6TH AVE TUCSON, AZ 85723-0001
[68392] SEPULVEDA OUTPATIENT & NURSING HOME CARE [CLIA# 05D0988216]
        16111 PLUMMER ST SEPULVEDA, CA 91343-2036
[72024] NICHOLS INSTITUTE 
          
[73367] QUEST REF LAB
          
===============================================================================
